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1. INTRODUCTION 
 
1.1. NEUROBLASTOMA 
 
1.1.1. HISTORY AND EPIDEMIOLGY 
 
Much research has been done on neuroblastoma (NB) since its discovery about 150 years ago. NB 
was originally described by Virchow in 1864, but thought it to be a glioma at that time (Virchow 
1864-65). NB was linked to the sympathetic ganglia in 1891, and Herxheimer was able to stain NB 
fibrils with special neural silver stain in 1914, providing further evidence for its origin (Marchand 
1891; Herxheimer 1914). Current thinking is that NB derives from primitive sympathetic neural 
precursor cells. This is based on the localization of NB in the adrenal gland or along the spinal cord 
in association with sympathetic ganglia and the neuroblastic phenotype of NB (Hoehner et al. 
1996).                                                    
 
NB is the second most common childhood cancer after leukemia in Germany, and is the most 
common solid extracranial pediatric tumor with an incidence of 1.1 cases in 100,000 children under 
15 years of age (Gadner H. 2005; Krebsgesellschaft 2010). The median age at diagnosis is 18 
months; with approximately 40 % of patients diagnosed by 1 year of age, 75 % by 4 years and 98 
% by 10 years of age (Goodman 1999; Brodeur GM 2006). 
 
 
1.1.2. CLINICAL PRESENTATION AND DIAGNOSIS 
 
NB has been called the “great mimicker” because it can appear in many different variations, related 
to the site of the primary tumor, metastatic disease and metabolic tumor by-products. While 
children with localized disease are usually asymptomatic, patients with disseminated NB are very 
sick and may have systemic manifestations, including unexplained fevers, weight loss, anorexia, 
failure to thrive, general malaise, irritability and bone pain. Tumors can develop anywhere along 
the sympathetic nervous system, but most (65 %) primary tumors occur within the abdomen, with 
at least half of these arising in the adrenal medulla. Other common sites include the neck, chest and 
pelvis (Brodeur GM 2006). Around 40 % of patients show a localized stage of disease. These 
tumors are often clinically asymptomatic and often incidentally diagnosed in routine screenings 
such as ultrasound diagnosis or chest radiographs. Cervical masses are sometimes associated with a 
Horner syndrome, which can be the first and/or only manifestation (Mahoney et al. 2006). Elevated 
blood pressure due to excess catecholamine concentrations occurs in some, but not all, patients 
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(Wargalla-Plate et al. 1995). About half of all NB patients are diagnosed with metastatic disease. 
NB has a tendency to metastasize to the orbita bone, which leads to periorbital ecchymoses 
(raccoon eyes) or proptosis, as classical signs for disseminated NB. Metastasis to bone and bone 
marrow occurs and can result in bone pain, limping or irritability. Bone marrow replacement and 
symptoms of marrow failure can also occur (Quinn et al. 1979). Taken together, NB presents itself 
in many heterogeneous ways, creating a diagnostic challenge.  
 
Laboratory diagnostics are powerful tools to detect NB and provide further evidence for NB if it is 
suspected. Patients can present with elevated erythrocyte sedimentation rates, normochromic 
anemia or unspecific elevation of lactate dehydrogenase or ferritin levels in serum.  Higher levels 
of these proteins may indicate rapid tumor growth and/or large tumor burden, and are rather used 
for follow-up and risk stratification than for diagnosis (Hann et al. 1985). Specific tumor markers 
for NB are elevated levels of catecholamine metabolites, such homovanillic acid and 
vanillylmandelic acid, in the urine. Large NB screening programs in the 1980s were based on 
detection of these tumor-derived catecholamines in spot urine samples, since it was believed that 
aggressive and biologically unfavorable disease stages evolved from more localized, biologically 
favorable tumors in infants. Since infants with NB were known to have a better outcome than 
children over 1 year of age at diagnosis, early detection was hypothesized to be capable of 
improving survival of NB patients. Studies in Japan showed that NB was detectable via urine 
screening at 6 months of age, and early results suggested that preclinical detection led to improved 
survival (Sawada et al. 1984).  However, subsequent reports from mass screening programs in 
Canada and Germany showed that screening did not reduce mortality. The incidence of NB 
increased in both of the screened populations, but almost all detected tumors showed favorable 
biological features and lower stages of disease (Schilling et al. 2002; Woods et al. 2002), indicating 
that the increased prevalence and incidence was due to NB detection in patients, whose tumors 
would have regressed or matured without developing symptomatic disease and without requiring 
therapeutic intervention (Brodeur et al. 2001). The cost of screening and the unchanged mortality 
rates argued against the usefulness of mass screening for NB in infants. Other serum markers of 
NB exist, such as neuron specific enolase (NSE), a cytoplasmic protein associated with neural 
cells. Survival was shown to be worse for patients with advanced disease and high serum NSE 
(Zeltzer et al. 1986). The GD2 protein is a disialoganglioside present on the surface of most NB 
cells, and increased levels have been detected in the plasma of NB patients (Mujoo et al. 1987). 
Gangliosides that are shed by tumor cells might be important in accelerating tumor progression. 
Since laboratory diagnostics are non-invasive, easy to perform and relatively inexpensive, they are 
not only important for NB diagnosis, but would be useful for stratification of high stage disease as 
novel markers become available. 
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Once NB is diagnosed, the staging and follow-up routine require other diagnostic tools. Ultrasound, 
MRI and meta-iodobenzylguanidine scintigraphy are used to define dissemination of the primary 
tumor and lymph node status. Bone marrow aspiration at four sites is used to exclude bone marrow 
infiltration, and spinal fluid is analyzed for tumor cells as well. If metastases are suspected, 
technetium imaging can be used (Leitlinie Hämatologie 2008). The choice of diagnostic tools 
depends on the stage of disease and available equipment, with the goal of achieving a complete 
picture of the current status of disease. 
 
 
1.1.3. HISTOPATHOLOGY AND STAGING 
 
Due to the heterogeneous presentation of NB, a good staging schema is important to prevent over- 
or undertreatment. However, including all features in one classification schema is a challenge. In 
1984, Shimada and colleagues proposed a classification schema, relating the histopathological 
features of the tumor to its clinical behavior. Tumors are classified as favorable or unfavorable, 
depending on the degree of neuroblast differentiation, Schwannian stroma content, mitosis-
karyorrhexis index (MKI) and age at diagnosis (Shimada et al. 1984). In subsequent studies, the 
Shimada system was then modified into the International Neuroblastoma Pathology Classification 
(INPC) which also takes the age of the patient into consideration (Shimada et al. 1999), and is now 
internationally recognized. The most important clinical variables in predicting patient outcome are 
the stage of disease as defined by the International Neuroblastoma Staging System (INSS). The 
INSS was developed by Evans in 1971 and was modified in 1993 by Brodeur (Evans et al. 1971; 
Brodeur et al. 1993). Five stages of disease are described by the INSS. Stage 1 defines a localized 
tumor, confined to the area of origin which is macroscopically resectable and only infiltrates lymph 
nodes in direct proximity. Stage 2a describes a unilateral tumor with incomplete gross resection 
where identifiable ipsilateral and contralateral lymph nodes are free of tumor material. Stage 2b 
describes a unilateral tumor that could be completely or incompletely resected, where ipsilateral 
lymph nodes are positive for tumor but contralateral lymph nodes are free of tumor material. Stage 
3 tumors infiltrate across the midline with or without regional lymph node involvement, are 
unilateral tumors with contralateral lymph node involvement or are midline tumors with bilateral 
lymph node involvement. Stage 4 describes a dissemination of the tumor to distant lymph nodes, 
bone marrow, bone, liver, or other organs except as defined by Stage 4S, which is limited to 
children under 1 year of age by definition and makes up about 5 % of NB cases. Patients show 
small localized primary tumors, similar to stages 1 or 2, but have metastases in the liver, skin or 
bone marrow, but never in the bone. A unique feature of this stage is that the tumor almost always 
spontaneously regresses or differentiates. Survival of patients with 4S NB is, therefore, up to 90 % 
(Nickerson et al. 2000). Different NB stages are treated with different protocols, making correct 
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staging essential. This diversity in the disease and its implication for patient treatment has spawned 
much research into biological and genetic factors of the tumors that could be diagnostically or 
prognostically helpful. 
 
 
1.1.4.  BIOLOGICAL AND GENETIC FACTORS 
 
1.1.4.1. Genomics of neuroblastoma 
Although NB usually occurs sporadically, 1 % to 2 % of patients have a family history of the 
disease. Familial neuroblastoma is inherited in an autosomal-dominant Mendelian fashion with 
incomplete penetrance. Affected children from these families differ from those with sporadic 
disease. They are often diagnosed at an earlier age and/or have multiple primary tumors (Maris et 
al. 1999), supporting the presence of germline mutations in one allele of tumor suppressor genes as 
a cause for familial NB. Knudson and Strong proposed that a new germinal mutation in a 
predisposition gene may account for the initiation of tumorigenesis in up to 22 % of nonfamilial 
cases, and that this predisposition follows an autosomal-dominant pattern of inheritance (Knudson 
et al. 1972). Various genetic alterations affecting NB are known, the most important of which are 
described below. 
 
MYCN amplification 
The genetic aberration most consistently associated with poor outcome in NB is the genomic 
amplification of MYCN.  It was initially observed that some NBs showed double-minute chromatin 
bodies or homogeneously staining regions (HSRs), both cytogenetic manifestations of gene 
amplification. Identification of a novel MYC-related oncogene, MYCN, in the amplified region was 
published in 1983 (Schwab et al. 1983). MYCN is amplified in approximately 20 % of primary 
tumors, and is strongly correlated with advanced disease stage and treatment failure. Even in 
infants and patients with lower disease stages is MYCN amplification associated with poor outcome 
(Brodeur et al. 1984). MYCN is a member of the MYC family, and encodes a nuclear protein with a 
basic helix-loop-helix (bHLH) domain, which is normally expressed during neurogenesis and 
required for organogenesis (Knoepfler et al. 2002). MYC oncoproteins are transcription factors that 
can cause deregulation of growth and proliferation when overexpressed. Reasons for the 
association of MYCN amplification with a more aggressive phenotype are still unclear, but the 
MYCN protein is also overexpressed in MYCN-amplified tumors. MYCN forms a heterodimer with 
the MAX protein, and this protein complex functions as a transcriptional activator. In the absence 
of MYCN, MAX forms a homodimer that is then transcriptionally repressive. Some MYCN targets 
include ODC, MCM7 and MRP1, and activation of these genes leads to progression through the G1 
phase of the cell cycle. Although the MYCN protein has a short half-life, the extremely high 
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steady-state levels in amplified tumor cells probably ensure that cells proceed through the cell cycle 
and do not enter G0 (Brodeur 2003). Due to the strong association with poor outcome, 
identification of MYCN amplification in a tumor of any stage classifies the patient as high-risk. 
 
 
1p deletion 
Deletions of the short arm of chromosome 1 (1p) are present in 25–35 % of neuroblastomas. These 
deletions correlate with MYCN amplification and also with advanced disease stage. The 
independent prognostic significance of 1p loss of heterozygosity (LOH) has been controversial, but 
Maris et al. showed that allelic loss at 1p36 predicts for disease progression but not decreased 
overall survival probability (Maris et al. 2000). 
 
11q deletion 
Allelic loss of 11q is detected in 35–45 % of primary NB, making it the most common deletion in 
NB, to date. MYCN-amplified tumors rarely have 11q deletions, but 11q deletions are strongly 
associated with 3p deletions, another high-risk feature (Plantaz et al. 2001). 
 
Trisomy of 17q 
Another karyotypic abnormality in NBs, is a gain of 1–3 additional copies of 17q. This occurs in 
more than half of all NBs, and is often a result of unbalanced translocation with chromosome 1 or 
11. Trisomy of 17q has also been correlated with a more aggressive disease phenotype (Bown et al. 
1999). 
 
DNA index 
Although most tumors have karyotypes in the diploid range, tumors from patients with lower 
disease stages are often hyperdiploid or near-triploid. Kaneko et al., showed the association of good 
patient prognosis with near-triploid tumors in infants with untreated NB (Kaneko et al. 1987). 
Ploidy is less prognostically significant in patients over 2 years of age. This is probably because 
hyperdiploid and near-triploid tumors from infants generally have whole chromosome gains 
without structural rearrangements, whereas these tumors in older patients have several additional 
structural rearrangements (Look et al. 1991).  
 
 
1.1.4.2. Biological factors involved in molecular pathogenesis of neuroblastoma 
Neurotrophin receptors and their ligands are important regulators of survival, growth, and 
differentiation of neural cells. Receptors are encoded by the NTRK1, NTRK2, and NTRK3 genes for 
TrkA, TrkB, and TrkC, respectively, which are activated by the ligands NGF, BDNF and 
neurotrophin-3. Biologically favorable NBs express high levels of TrkA, and high NTRK1 
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expression strongly correlates with patient survival and younger age, while aggressive, MYCN-
amplified NBs express little or no NTRK1 (Nakagawara et al. 1993). TrkA also promotes growth 
inhibition and neuronal differentiation when expressed in the human NB cell line, SH-SY5Y, 
which has a single copy of MYCN (Eggert et al. 2000). TrkB and BDNF expression are associated 
with NBs that show MYCN amplification and are classified as high-risk tumors (Nakagawara et al. 
1994). A hypothetical model based on these observations was devised for the genetic origin of 
neuroblastoma (Fig.1).  
 
Fig. 1: Hypothetical model of the genetic origin of neuroblastoma. Mutations in undifferentiated neuroblasts 
cause tumorigenesis, and the degree of neuroblastic differentiation at the time of the mutation determines 
neurotrophin expression pattern. TrkA-expressing tumors are more likely to have errors in mitotic 
recombination, resulting in whole chromosome gains. They are called “type 1 tumors”, are often near triploid 
(3n) and can differentiate in response to NGF or undergo programmed cell death in the absence of NGF. 
TrkB-expressing tumors (“type 2 tumors”) show more genomic instability, with structural chromosomal 
alterations. They often have unbalanced gain of distal 17q material, loss of 11q and/or 14q material and are 
often without 1p deletion and MYCN amplification. Tumors with 1p loss (by unbalanced translocation or 
other mechanisms) often contain MYCN amplification (type 3 tumors). Thus, inactivation of a 1p gene may 
be a prerequisite for MYCN amplification (Maris et al. 1999) 
 
 
1.1.5. RISK STRATIFICATION AND THERAPY 
 
Risk assessment for NB patients depends on several clinical and biological features and the INSS 
stage of disease. To countermand the great variability in risk assessment worldwide, a working 
group developed the International Neuroblastoma Risk Group (INRG) classification system in 
2005. It is based on clinical criteria and tumor imaging and includes age, histological category, 
grade of tumor differentiation, DNA ploidy and status of the MYCN oncogene and chromosome 
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11q. The extent of locoregional disease is determined by the absence or presence of image-defined 
risk factors (L1 and L2, respectively). Stage M is used for widely disseminated disease, and MS 
describes metastatic NB limited to skin, liver and bone marrow, without cortical bone involvement 
in children up to 18 months with L1 or L2 primary tumors. An overview of the INRG Consensus 
Pretreatment Classification schema is shown in Fig. 2. This schema is currently used to classify the 
patient into a defined pretreatment risk group, and allows risk-adapted therapy (Ambros et al. 2009; 
Cohn et al. 2009). Current studies also include novel biomarkers to investigate their prognostic 
significance and consider their inclusion in future classifications systems. Co-amplification of 
several genes, including DDX1, NAG, and ALK, with MYCN has been observed in NBs and HER2 
expression is also suspected to be a marker for positive prognostic significance in NB (Izycka-
Swieszewska et al 2010; Ambros et al. 2009). Although only few biomarkers are included in the 
current classification systems, high-throughput and high-coverage genetic and expression profiling 
of NBs has the power to deliver new markers for defining risk groups more precisely and indicating 
targeted therapies. 
 
 
Fig. 2: International Neuroblastoma Risk Group (INRG) Consensus Pretreatment Classification schema 
(taken from Cohn et al. 2009). GN, ganglioneuroma; GNB, ganglioneuroblastoma; Amp, amplified; NA, not 
amplified; L1, localized tumor confined to one body compartment and with absence of image-defined risk 
factors (IDRFs); L2, locoregional tumor with presence of one or more IDRFs; M, distant metastatic disease 
(except stage MS); MS, metastatic disease confined to skin, liver and/or bone marrow in children < 18 
months of age; EFS, event-free survival. 
 
Treatment of neuroblastoma is heterogenous and depends on various factors defining the specific 
risk group of the patient. Low-stage tumors are usually localized, and are surgically removed 
without chemotherapy. Moderate chemotherapy is only applied in these cases for patients who 
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experience tumor progression or relapse. Stage 4S tumors may regress spontaneously, and are often 
only observed without any treatment. Mild chemotherapy may be applied in cases where other 
organs are affected to induce regression. Treatment of high-risk patients requires maximum 
therapy, which may include surgical removal of the tumor, chemotherapy and/or radiotherapy as 
well as bone marrow transplantation (Matthay et al. 1999). Treatment with retinoic acid to induce 
tumor differentiation of residual tumor cells that are resistant to cytotoxic agents may be included 
as an additional therapeutic option after transplantation or chemotherapy  (Matthay et al. 1999).  
 
Chemotherapy consists of combinations of multiple cytostatic agents, and is applied within 
controlled studies and according to a protocol, depending on the stage of disease. Treatment 
protocols may include combinations of alkylating agents (such as ifosfamide, dacarbazine), 
anthracyclines (adriamycin), etoposide, melphalan, cisplatin and vinca alkaloids (vincristine, 
vindesine). Duration of therapy may be up to two years, depending on the stage of disease 
(Hämatologie 2008). All of these agents are prone to induce resistance in tumor cells over time 
(Kotchetkov et al. 2003; Raguz et al. 2008; Boegsted et al. 2011), especially in progressive disease, 
which remains a problem in therapy. While low-risk NB patients have good overall survival, cure 
rates for tumors of INSS stages 3 and 4 are only 13–38 % (Chan et al. 1997). This poor patient 
survival and the danger of developing resistance underscore the need for a more targeted 
therapeutic approach to more effectively treat high-risk patients 
 
 
1.1.6. RELAPSE AND RESISTANCE IN NB 
 
One of the main treatment problems of NB is the particular tendency of NB cells to develop 
resistance to cytostatic agents. Tumor cells from relapse patients have been shown to have 
increased resistance to standard cytostatic treatment in comparison to control cells (Keshelava et al. 
1997). Different mechanisms including elevated efflux, prohibiting accumulation of the toxins in 
the cell, have been shown to be involved in the development of resistance. The best known 
mechanism of multidrug resistance involves increased expression of the adenosine triphosphate–
dependent efflux pump, P-glycoprotein. The PGY1 gene (previously named MDR1) at chromosome 
7q21.1 encodes the ubiquitously expressed P-glycoprotein. Chan et al. reported that P-glycoprotein 
expression was restricted to advanced-stage tumors and correlated with a poor response to 
chemotherapy, but other groups were unable to confirm these findings (Chan et al. 1991; Dhooge et 
al. 1997). PGY1 mRNA expression was reported to be inversely correlated with MYCN mRNA 
expression in NBs, and appeared to be restricted to normal stromal cells in the primary tumors. 
Chemoresistance in widespread NB is therefore less likely to be associated with P-glycoprotein 
expression (Favrot et al. 1991; Nakagawara et al. 1991). MRP (multidrug resistance-related 
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protein) encodes another multidrug resistance-associated protein. Norris et al. showed that MRP 
gene expression in primary NBs was strongly correlated with MYCN oncogene amplification and 
poor outcome (Norris et al. 1996). The presence of E-box consensus sequences in the MRP 
promoter region supports potential transcriptional regulation by MYCN (Zhu et al. 1994). High 
telomerase activity can also immortalize cancer cells. This reverse transcriptase extends the 
telomere ends of chromosomes, enabling cells to overcome cell death. High telomerase activity 
was reported in NB cases and was correlated with MYCN amplification and unfavorable patient 
prognosis (Hiyama et al. 1995). These reports show that resistance can develop via several 
mechanisms in NB.   
 
 
1.2. DNA REPAIR MECHANISMS AND DEVELOPMENT OF RESISTANCE 
 
Enhanced repair protects cellular DNA from damage and can also promote resistance in cancer 
cells. Five major repair mechanisms have been described to date: nucleotide excision repair (NER), 
mismatch repair (MMR), double-strand break repair, base excision repair (BER) and direct repair. 
Major forms of DNA damage include single-strand breaks, double-strand breaks, base alteration, 
hydrolytic depurination, hydrolytic deamination of cytosine and 5-methylcytosine bases, formation 
of covalent adducts as well as oxidative damage to the bases or phosphodiester backbone. The vast 
majorities of these lesions are repaired by BER, NER and MMR (Norbury et al. 2001). 
 
Nucleotide excision repair 
NER is a highly conserved DNA repair pathway for lesions which alter the helical structure of the 
DNA molecule, thus, interfering with replication and transcription. It has been proposed as the key 
pathway involved in mediating resistance or sensitivity to platinating chemotherapeutic agents 
(Rabik et al. 2007). Cisplatin was the first platinating agent approved for cancer treatment and is 
still a part of the standard multimodal treatment protocol for NB. Cisplatin and its analog, 
carboplatin, work by binding to DNA and forming DNA adducts. These adducts lead to intrastrand 
or interstrand cross-links, which disrupt the structure of DNA molecules, causing steric changes in 
the helix (Rabik et al. 2007). The distorted DNA structure inhibits replication and transcription, 
and, if not repaired, leads to cell death via apoptosis (Boeckman et al. 2005). Important steps in this 
repair mechanism include the recognition of DNA damage and demarcation of the affected area, 
followed by the formation of a complex to unwind the damaged portion and excise it. The excised 
area is then re-synthesized and ligated to maintain the complete DNA molecule. The excision 
repair cross-complementation group 1 (ERCC1) protein plays a key role in NER. ERCC1 dimerizes 
with xeroderma pigmentosum complementation group F, and the resulting complex is required for 
the excision of damaged DNA (Martin et al. 2008). Since cisplatin is used in NB treatment, 
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modifications of the NER pathway that lead to enhanced repair capacity might be involved in the 
development of resistance. 
 
Mismatch repair  
MMR is a strand-specific repair pathway that follows a stepwise process, initiated by recognition 
of DNA damage (Kunkel et al. 2005). MMR proteins are called Mut proteins. They recognize 
mismatched or unmatched DNA base pairs or insertion-deletion loops, and initiate the assembly of 
a protein complex that excises the affected area. DNA is then resynthesized by DNA polymerase. 
Without intact MMR, unrepaired areas of DNA accumulate when unrepaired base pair mismatches 
are replicated during DNA synthesis, and repeats are formed due to slippage of the synthetic 
complex at these areas, leading to microsatellite instability. A functional MMR system is required 
for the detection of damaged DNA created by cisplatin or carboplatin (Aebi et al. 1996). Platinating 
chemotherapeutic agents interfere with normal MMR activity and prevent the completion of repair, 
which then leads to DNA damage and apoptosis. When MMR is deficient, cells can continue to 
proliferate in spite of DNA damage caused by platinating agents, and are thus resistant.  MMR, as 
well as NER, is important for repairing cisplatin-induced damage, and therefore, might be involved 
in development of resistance against this drug. The recognition of cisplatin-induced DNA damage 
via MMR has been reported to be important for cisplatin-mediated cytotoxicity (Sedletska et al. 
2007). Cisplatin treatment has been reported to enhance the interaction between the MLH1 MMR 
protein, the PMS2 (postmeiotic segregation increased 2) protein and p7, triggering apoptosis in 
mismatch repair-proficient cells (Shimodaira et al. 2003). However, the repair function of MMR 
proteins has been shown to be uncoupled from their involvement in cisplatin-induced cell death 
(Basu et al. 2010). Taken together, these findings suggest that MMR is involved in repairing 
cisplatin adducts. 
 
Double-strand break repair 
Double-strand breaks (DSBs) are induced by a variety of genotoxic agents, such as ionizing 
radiation or cytotoxic agents, but are also frequently generated during normal cellular processes 
such as DNA replication (Cahill et al. 2006). Two main mechanisms are involved in DSB repair: 
nonhomologous end joining (NHEJ) and the homologous recombination (HR). HR is 
predominantly utilized by bacteria and lower eukaryotes, while NHEJ predominates in higher 
eukaryotes, especially in cells of complex multicellular organisms, such as mammals (Fattah et al. 
2010) 
 
Nonhomologous end joining 
The term was coined in 1996 by Moore and Haber because the break ends are directly ligated 
without requiring a homologous template (Moore et al. 1996). At least seven proteins are required 
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for NHEJ: Ku70, Ku86, the DNA-dependent protein kinase catalytic subunit DNA-PKcs, Artemis, 
X-ray cross complementing 4 (XRCC4), XRCC4-like factor (XLF) and DNA ligase IV (LIGIV). 
Ku proteins were named based on protein gel mobilities (actually 70 kDa and 83 kDa) of 
autoantigenic proteins from a scleroderma patient with the initials, “K.U.”. Ku86 is also referred to 
as Ku80 (Lieber 2010). Ku70 and Ku86 form a basket-shaped heterodimer (Ku) that slides onto the 
DNA ends, translocates inwards and binds to broken DNA ends. Ku protects the ends from 
exonucleolytic attack and recruits DNA-PKcs, a phosphoinositol-3-like family serine/threonine 
protein kinase. Together, Ku70, Ku86 and  DNA-PKcs form the trimeric DNA-dependent protein 
kinase complex and the assembly of this complex on the ends of double-stranded DNA activates 
the kinase activity of DNA-PKcs. DNA-PKcs, in turn, phosphorylates and activates the artemis 
nuclease, which facilitates ‘‘clean up’’ of the ends. Finally, ligation of the broken ends is catalyzed 
by the trimeric LIGIV complex, which consists of a catalytic core (DNA LIGIV) and its two 
accessory factors, XLF and XRCC4 (Fattah et al. 2010). The role of NHEJ in repair of ionizing 
radiation-induced double-strand breaks is well established (Lieber 2010), but is also connected to 
cisplatin-induced lesions, since cisplatin sensitizes the cells to ionizing radiation via inhibition of 
NHEJ (Boeckman et al. 2005). 
 
Base excision repair 
BER repairs damaged DNA throughout the cell cycle and is primarily responsible for removing 
small base lesions that do not distort the helix. While the related NER pathway repairs bulky helix-
distorting lesions, BER is important for removing damaged bases that could otherwise cause 
mutations by mispairing or lead to DNA breaks during replication. BER is initiated by DNA 
glycosylases that recognize and remove damaged or incorrect bases, forming apurinic/apyridinic 
(AP) sites, which are then cleaved by an AP endonuclease. The resulting single-strand break can 
then be repaired by short-patch replacing of a single nucleotide or long-patch BER, where 2-10 
new nucleotides are synthesized (Liu et al. 2007). 
 
Direct repair 
Another way to remove mutations is via direct reversal of the lesion. No template is needed, since 
the type of damage is specific for each of the four bases. Pyrimidine dimers formed by UV 
irradiation, resulting in an abnormal covalent bond between the adjacent pyrimidine bases can be 
repaired in this way. The photolyase enzyme directly reverses this damage (Sancar 2003). Another 
example is the methylation of guanine, which can be directly reversed by the O-6 methylguanine-
DNA methyltransferase (Sassanfar et al. 1991).  
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1.3. THE Y-BOX BINDING PROTEIN 1 (YB-1)  
 
1.3.1.  STRUCTURE OF YB-1 
 
YB-1 was first described in 1988 as a transcription factor that binds to the Y-box of MHC class II 
promoters (Didier et al. 1988), and belongs to the family of "cold-shock domain” (CSD) proteins. 
Cold-shock proteins are expressed in bacteria for protection against low temperatures, the most-
primitive stress that organisms can be exposed to (Jones et al. 1994; Jurchott et al. 2003). In 
eukaryotes, 40 % of the nucleic acid-binding region of the CSD protein family is homologous to 
the bacterial cold shock protein. Eukaryotic Y-box-binding proteins are not known to be involved 
in the cold-shock response, however, they are thought to play a role in a wide variety of 
environmental stress reactions (Kohno et al. 2003). Proteins that contain CSDs belong to the most 
evolutionarily conserved family of nucleic acid-binding proteins known among bacteria, plants and 
animals. Based on their broad DNA/RNA-binding properties, a myriad of cellular functions have 
been ascribed to CSD proteins.   
 
The YB-1 gene is located on chromosome 1p34 and contains 8 exons spanning 19 kb (Toh et al. 
1998). Several transcription initiation sites have been identified, and the 5’ UTR of the major 
initiation site is extremely long and thought to be involved in regulating gene expression. The YB-1 
mRNA contains approximately 1.5 kb, and encodes a 43 kDa protein with 324 amino acids. 
Homology searches reveal five pseudo genes present on chromosomes 3, 7, 9, 14 and 15 (Kohno et 
al. 2003). YB-1 is also known as dbpB. A number of closely related genes have been identified, 
including dbpA and dbpC (Fig. 3). The sizes of exons 2, 3 and 4 are well conserved within these 
three genes, and codon splitting within the CSD is also similar (Kudo et al. 1995; Tekur et al. 
1999).  
 
Fig. 3:  Schematic representation of the structure of Y-box binding proteins A/P = alanine/proline-rich 
region, CSD = cold-shock domain, B/A = base/acid repeats (taken from Kohno et al., 2003). 
 
 
YB-1 proteins contain three domains: A variable N-terminal domain region (aa 1-50), the highly 
conserved cold-shock domain (CSD, aa 51-129) and a C-terminal domain (130-C) (Wolffe 1994). 
The N-terminal domain is rich in alanine and proline residues and is thought to be a transactivation 
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domain (Kohno et al. 2003). The CSD is one of the most evolutionary conserved nucleic acid-
binding protein domain between bacteria and eukaryotes identified (Wolffe 1994). It comprises a 
five-stranded β-barrel and belongs to the β-sheet RNA-binding protein group with conserved RNP 
motifs (Graumann et al. 1996).  It binds RNA as well as double-stranded and single-stranded DNA 
(Wu et al. 2007). The structure of the C-terminal domain varies significantly in different 
organisms, these structural alterations may have been necessary for the evolution from 
poikilotherms to homoiotherms, and may be involved in the pleiotropic functions of Y-box-binding 
proteins (Kohno et al. 2003). The C-terminus is thought to be involved in protein–protein 
interactions since it contains alternate regions of basic or acidic amino acids, each of about 30 
amino acids in length, termed charged zipper or B/A repeats (Wu et al. 2007). This domain has also 
been shown to have a strong affinity for single-stranded DNA/RNA in vitro, and is most probably 
involved in nucleic acid binding (Izumi et al. 2001). Both a noncanonical nuclear localization 
signal and a cytoplasmic retention site within the C-terminal region of YB-1, which control cellular 
localization, allowing YB-1 to shuttle between the cytoplasm and nucleus (Kohno et al. 2003). The 
CSD also reportedly co-operates with the C-terminus to facilitate nuclear trafficking (Jurchott et al. 
2003). Taken together, each domain has unique features and is involved in multiple functions of 
YB-1, as summarized in Fig.4. 
 
Fig. 4:  Schematic diagram of the functional domains of YB-1. YB-1 contains an N-terminal domain, a cold-
shock domain (CSD) and a C-terminal domain (CTD). The N-terminal domain is thought to be involved in 
transactivation. The CSD is important for RNA/DNA binding. Most of the characterized protein-protein 
interactions occur with regions within the CTD. The CSD and CTD also work together to facilitate nuclear 
trafficking. The CTD contains a nuclear localization signal (NLS) and a cytoplasmic retention signal (CRS).  
(Adapted from Wu et al. 2007). 
 
 
1.3.2.  FUNCTIONS OF YB-1   
 
YB-1 is involved in numerous functions at all levels of the cell. It is expressed throughout 
embryogenesis and is one protein regulating cell proliferation. It is involved in early mouse 
development, homozygous knockout of YB-1 in mice leads to impaired neural tube closure and is 
embryonically lethal. Mice exhibit exencephaly with abnormal patterns of cell proliferation within 
the neuroepithelium (Uchiumi et al. 2006). The level of YB-1 expression is closely correlated with 
the level of cell proliferation (Lu et al. 2005). YB-1 is also induced in response to mitogenic stimuli 
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in various cell types, such as in T cells following cytokine stimulation (Sabath et al. 1990) as well 
as in endothelial cells (Stenina et al. 2000). 
 
YB- functionality is controlled by the abundance, location and phosphorylation status of the protein 
within the cell. Cellular translocation of YB-1 greatly influences its function, and correlates with 
specific characterists of tumors. In the cytoplasm, YB-1 regulates mRNA stability and translational 
regulation (Evdokimova et al. 2001; Fukuda et al. 2004), while in the nucleus, it regulates 
transcription of genes containing the Y-box promoter element (Kohno et al. 2003). YB-1 is mainly 
localized in the cytoplasm, but treatment of cells with anticancer drugs, hyperthermia or UV 
radiation has been shown to result in protein translocation to the nucleus (Koike et al. 1997; Stein 
et al. 2001). This translocation may, at least in some cells, be dependent on the status of the p53 
tumor suppressor protein, since Zhang et al., showed that nuclear translocation of YB-1 after 
cisplatin treatment or adenoviral infection required wild-type p53 (Zhang et al. 2003). Nuclear 
translocation has also been shown to be cell cycle regulated, with YB-1 protein accumulating in the 
nucleus during G1/S phase (Jurchott et al. 2003). YB-1 cellular abundance is at least partly 
regulated via proteosomal degradation. The F-Box protein 33 and RB binding protein 6 (RBBP6) 
are among the proteins targeting YB-1 for proteosomal degredation via polyubiquination (Lutz et 
al. 2006; Chibi et al. 2008). Initially, it was thought that nuclear translocation of YB-1 in response 
to genotoxic stress required sequence-specific endoproteolytic cleavage (Sorokin et al. 2005). But 
in 2009 Cohen et al. showed that only the larger form of YB-1 exists, and that the smaller protein 
band observed on western blots and thought to be YB-1, was an artifact of antibody cross-reactivity 
(Cohen et al. 2009). The C-terminal tail of YB-1 contains multiple phosphorylation sites that allow 
regulation of YB-1 functions (Kohno et al. 2003). Akt/PKB is a serine/threonine kinase that 
promotes tumor cell growth by phosphorylating transcription factors and cell cycle proteins, and 
activated Akt phosphorylates Ser102 of YB-1 (Sutherland et al. 2005). Phosphorylation of YB-1 
regulates nuclear translocation (Basaki et al. 2006), activates cap-independent translation 
(Evdokimova et al. 2009) and reduces binding to the mRNA cap (Bader et al. 2008). 
Phosphorylated YB-1 also upregulates PI3K activity, which is known to lead to transformation 
through the ras pathway (Astanehe et al. 2009), and is required for transcriptional activation of 
growth-enhancing genes, such as EGFR (Wu et al. 2006).  
 
The consensus binding site for YB-1 was defined as 5’-CTGATTGG-3’, a sequence motif known 
as the Y-box, which contains an inverted CCAAT box sequence (Didier et al. 1988). This motif is 
present in the promoter regions of many eukaryotic genes, such as growth-associated genes, the 
major histocompatibility complex class II (MHC II) genes or the PGY1 gene (Wolffe et al. 1994).  
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YB-1 regulates gene expression via three different mechanisms. (Swamynathan et al. 1998). 
Interaction of YB-1 with the Y-box consensus motif is known to either activate or repress gene 
expression (Ohga et al. 1998). Additionally YB-1 is involved in translational control (Evdokimova 
et al. 2001; Gaudreault et al. 2004). YB-1 directly activates transcription of a number of genes. It 
binds to the inverted CCAAT box and enhances transcription of cell cycle proteins (Jurchott et al. 
2003) and several genes, involved in replication, such as topoisomerase II or DNA polymerase α 
and δ  (Shibao et al. 1999; En-Nia et al. 2005). A recent report for breast cancer cells also claims 
that YB-1 activates genes, linked to cancer stem cells such as CD44 and CD49f (To et al. 2010). 
YB-1 has been shown to mediate repression of genes involved in cell death regulation, including 
p53 (Lasham et al. 2003), genes coding for structural proteins (Higashi et al, 2003) or metabolic 
proteins (Chen et al. 2009). In addition to transcriptional regulation, YB-1 is also implicated in 
translational control. It positively regulates translation of Myc oncoproteins via an alternative 
method, using internal ribosome entry segments (IRES). YB-1 also interacts with and stabilizes 
mRNA in a sequence non-specific, but cap-dependent manner (Evdokimova et al. 2001). Binding 
of YB-1 displaces the initiation factors eIF4E (eukaryotic translation initiation factor 4E) and 
eIF4G and thereby causes translational silencing of the bound mRNA (Evdokimova et al. 2001). 
Microarray analysis revealed, that YB-1 interacts with and silences a large set of mRNAs, among 
them mRNA´s coding for cyclins and members of the mitogen-activated protein kinase cascade 
(Evdokimova et al. 2006). YB-1 has also been shown to preferentially bind to RNA containing 8-
oxoguanine, suggesting it can detect damaged RNA molecules (Hayakawa et al. 2002). Taken 
together, YB-1 participates in controlling expression at several levels, localized in either the 
nuclear or cytoplasmic compartments. The involvement of YB-1 in the control of so many different 
types of proteins highlights its significance in cellular functions, and underpins its involvement in 
the central processes of cancer progression. 
 
 
1.3.3. YB-1 AND CANCER 
 
YB-1 has been linked with many malignancies including colorectal carcinomas (Shibao et al. 
1999), breast cancer (Bargou et al. 1997), prostate cancer (Gimenez-Bonafe et al. 2004), 
osteosarcoma (Oda et al. 2003), ovarian  cancer (Kamura et al. 1999), melanoma (Schittek et al. 
2007) and lung cancer (Shibahara et al. 2001). Especially the role of YB-1 in breast cancer has 
been intensively researched. YB-1 directly induced transcription of the human epidermal growth 
factor receptor (her-2) and its dimerization partner, EGFR, and targeting YB-1 via siRNA drugs 
induced apoptosis in breast cancer cells with her-2 amplifications (Lee et al. 2008). Transgenic 
mice overexpressing YB-1 in a breast-specific manner were highly prone to developing tumors, 
and the tumor cells were genetically unstable (Bergmann et al. 2005). Janz et al., showed that YB-1 
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expression correlated with breast cancer aggressiveness in patients not treated with postoperative 
chemotherapy. At 5 years following surgical removal of the primary tumor, patients whose tumors 
expressed low levels of YB-1 remained free of disease, whereas 30 % of patients with tumors 
strongly expressing YB-1 had experienced relapses (Janz et al. 2002). Much less is known about 
the role of YB-1 in childhood cancers. YB-1 overexpression has been described for pediatric 
glioblastoma, (Faury et al. 2007) and YB-1 expression was recently assessed in a small cohort of 
36 NBs via immunohistochemistry (Wachowiak et al. 2010). YB-1 expression was detected in 35 
of 37 (94.6 %) NBs, but YB-1 expression did not correlate with survival, risk factors or tumor 
stage. YB-1 expression in other tumor compartments has also associated it with angiogenesis. The 
endothelial cells of brain tumor microvasculature and microvessels in the desmoplastic region 
surrounding multiple solid tumors expressed high levels of YB-1. YB-1 knockdown was also 
shown to inhibit the growth of human umbilical vein endothelial cells in culture (Takahashi et al. 
2010). Elevated expression of YB-1 is observed in the tumor cells and tumor vasculature of many 
tumor types and YB-1 overexpression can be clearly linked to a more aggressive form in some of 
these malignancies. 
 
Nuclear localization of YB-1 has been associated with indicators of more aggressive cancer 
subtypes. Nuclear localization of YB-1 was associated with PGY1 expression in breast carcinomas 
(Bargou et al. 1997), sarcomas (Oda et al. 2003) diffuse large B cell lymphomas (Xu et al. 2009) 
and ovarian carcinomas (Kamura et al. 1999). Nuclear YB-1 expression correlated with high levels 
of proliferation, drug resistance and poor patient prognosis (Jurchott et al. 2003; Homer et al. 2005; 
Sutherland et al. 2005).  Nuclear YB-1 was associated with poor prognosis of patients with non-
small cell lung cancer (Shibahara et al. 2001) and sarcomas (Oda et al. 2003). A recent study also 
linked nuclear YB-1 expression in human breast cancer cells closely to progesterone receptor 
negativity and catagorized this as a strong adverse survival factor (Dahl et al. 2009). Nuclear 
expression of YB-1 in diffuse large B cell lymphomas was significantly correlated with clinical 
stage, bone marrow involvement, extra nodal involvement and poor response to chemotherapy (Xu 
et al. 2009). Patients with ovarial carcinomas expressing higher nuclear YB-1 concentration had 
poorer prognoses, with shorter relapse-free periods (Kamura et al. 1999).    
 
 
1.3.4.  YB-1, CYTOSTATICS AND RESISTANCE 
 
High YB-1 expression is associated with poor patient outcome in various cancers. One study 
reported that 66 % of patients with breast cancer whose tumors expressed high levels of YB-1 
experienced relapses within 5 years of completing treatment, whereas, no patient experienced 
relapse whose tumor expressed low YB-1 levels (Janz et al. 2002). This high rate of relapse may 
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reflect an advantage for cells with elevated YB-1 expression on development of resistance to drugs 
used during initial patient treatment. Ohga et al., discovered back in 1996 that knockdown of YB-1 
sensitized cells to cisplatin, mitomycin C and UV radiation, but not to vincristine, doxorubicin, 
campothecin or etoposide (Ohga et al. 1996). In 2004, Shibahara et al., showed that mouse 
embryonic stem cells expressing heterozygous YB-1 were hypersensitive to cisplatin and 
mitomycin C (Shibahara et al. 2004). These findings suggest that YB-1 has a protective capacity 
against cytotoxic effects of DNA damaging agents. YB-1 binds preferentially to cisplatin-modified 
DNA and interacts with proliferating cell nuclear antigen 1 (PCNA), which may mean that YB-1 
can function as a recognition protein for DNA damaged by platinating compounds, such as 
cisplatin (Ise et al. 1999). Total expression as well as nuclear localization of YB-1 have been 
associated with a functional response to DNA-damaging agents. Expression profiling revealed that, 
among others, YB-1 was upregulated in fibrosarcoma cells resistant to a diverse group of DNA-
interactive agents, including cytarabine, etoposide or doxorubicin (Levenson et al. 2000).  Global 
expression profiles from breast cancer cell lines contained YB-1 in several chemoresistance 
signatures (Guay et al. 2008). The importance of nuclear localization in predicting development of 
drug resistance has been described for several cancer entities, including breast cancers, ovarian 
cancers, and synovial sarcomas (Janz et al. 2002; Oda et al. 2003). Basaki et al. described the role 
of Akt-mediated activation of YB-1, which is required for nuclear translocation, in acquisition of 
drug resistance through transcriptional activation of relevant genes and repair of damaged DNA 
(Basaki et al. 2006). 
 
The PGY1 gene is important in the development of resistance against cytostatic agents. PGY1 is an 
SOS gene, its promotor activity is increased in response to environmental stress including various 
anticancer agents (Chaudhary et al. 1993), UV radiation  (Uchiumi et al. 1993) or heat shock 
(Miyazaki et al. 1992). Its product, P-glycoprotein, is a 170 kDa transmembrane protein, belonging 
to the ATP-binding transporter family, that actively effluxes many drugs from cells, and is 
responsible for tumor cell resistance to a range of anticancer drugs (Kuwano et al. 2004). The 
PGY1 promoter also contains a Y-box motif, and YB-1 has been shown to bind to it (Swamynathan 
et al. 1998) and activate transcription of PGY1 (Stein et al. 2001; Chattopadhyay et al. 2008). 
Different reports described that nuclear, but not cytoplasmic, YB-1 correlated with increased PGY1 
expression (Bargou et al. 1997; Fujita et al. 2005).  
 
 
1.3.5.  YB-1 AND REPAIR 
 
YB-1 has been connected with several different repair pathways. It was identified among other 
protein binding partners of base-excision repair enzymes in a yeast two-hybrid screen in 2001 
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(Marenstein et al. 2001). Gaudreault et al., showed three years later that purified YB-1 can separate 
different DNA duplexes containing forked structures or blunt, 5' or 3' recessed ends, and that strand 
separation activity increases around cisplatin-modified DNA or mismatch-containing DNA 
duplexes. They showed that YB-1 exhibited exo- and endonucleolytic activities and bound to 
Ku80, MSH2, WRN and DNApol δ in vitro, repair proteins involved in base-excision and 
mismatch repair (Gaudreault et al. 2004). YB-1 has been shown to bind cisplatin-modified DNA 
and interact with PCNA, which acts as a processing factor for DNA polymerase δ in eukaryotic 
cells, implicating its involvement in resynthesis of excised, damaged DNA strands during DNA 
repair (Ise et al. 1999). YB-1 also interacts with NEIL2, one of the four oxidized base-specific 
DNA glycosylases, and was reported to stimulate its base-excision activity in human colon 
carcinoma HCT116 cells (Das et al. 2007).  The same report showed that YB-1 interacted with the 
other NEIL2-associated BER proteins in vitro, including DNA ligase IIIα and DNA polymerase β. 
It was speculated that YB-1 may be a component of a large multiprotein complex formed by these 
factors (Das et al. 2007). 
 
 
1.3.6.  YB-1 AND APOPTOSIS 
 
Various connections have been described between YB-1 and p53, a tumor suppressor protein 
rendered disfunctional in more than 50 % of all cancers and a cellular gatekeeper halting 
proliferation in response to cellular stress, and capable of initiating either senescence or apoptosis 
(reviewed in Suzuki et al. 2011). p53 exibits growth suppressive properties by transcriptional 
regulation of gene expression. Genes directed by p53 within the DNA damage response pathway 
include p21/Waf1/Cip1 (el-Deiry et al. 1993) and bax (Reed et al. 1995). By modulating expression 
levels of these genes, p53 can induce either cell arrest or apoptosis under genotoxic stress through 
cell cycle checkpoints to ensure genetic stability. Okamoto described a model of induction of p53 
activity after DNA damage implicating it in repair. When DNA damage leads to single-stranded 
regions, DNA ends, and insertion/deletion mismatches, p53 is recruited to the damaged region via 
the high binding affinity of its C-terminus for these structures, and interaction with other repair-
associated proteins, including RPA, XPB, and XPD, also cause p53 accumulation. Sequence-
specific DNA binding activity is then stimulated by short, single-stranded DNA produced in 
process of NER or by other modification of the C-terminal regulatory domain (Okamoto et al. 
2000). YB-1 has also been reported to accumulate in the nucleus under conditions of genotoxic 
stress and associates with single-stranded, apurinic, or cisplatin-adducted DNA. It was shown in 
various cell lines after treatment with the antitumor drugs cisplatin, actinomycin D and amsacrine 
as well as adenovirus infection that wild-type p53 is necessary for YB-1 translocation while 
mutated p53 protein is defective for nuclear localization. A possible interaction of YB-1 and p53 in 
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the DNA damage region to mediate repair and activate the specific DNA-binding activity of p53 
was proposed in 1997 (Koike et al. 1997). Direct interaction of p53 with YB-1 has been described 
by different working groups, who showed that YB-1 prevents p53 from inducing apoptosis by 
selectively inhibiting its transactivation of proapoptotic genes. (Okamoto et al. 2000; Homer et al. 
2005). Lasham et al., reported that YB-1 can negatively regulate p53 by reducing its endogenous 
cellular level in various cell lines of mouse and human origin, thus, reducing activity. This same 
report showed that nuclear YB-1 was associated with a failure to increase the level of Bax protein 
in normal mammary epithelial cells after stress activation of p53 (Lasham et al. 2003). From these 
reports, it appears that YB-1 may be capable of protecting cells from p53-induced apoptosis, thus, 
assisting tumor cells in escaping death by upregulating and/or translocating YB-1 to the nucleus.  
 
 
1.3.7.  YB-1 AND MYCN 
 
Upregulation of the MYCN protein via either MYCN amplification or other mechanisms is an 
important factor for neuroblastoma aggressiveness, therefore, connections between the MYC 
protein family and YB-1 could be of importance specifically for neuroblastoma. The MYC family 
of transcription factors regulate gene transcription via binding to the DNA sequence, CACGTG, 
called E-box in the gene promoter. The YB-1 promoter contains an E-box motif, making it a 
potential MYCN target (Wu et al. 2007). The proto-oncogenes, c-, L-, and MYCN, can all be 
translated via an alternative method where the ribosome is recruited to a complex structural 
element, termed an internal ribosome entry segment (IRES). YB-1 was shown to positively regulate 
IRES-mediated translation of c-, L-, and MYCN both in vivo and in vitro (Cobbold et al. 2008). 
Another connection can be made through the Twist protein, an E-box-binding transcription factor. 
Twist is constantly overexpressed in MYCN-amplified neuroblastomas as well as in cisplatin-
resistant human epidermoid cancer KB and human prostate cancer PC3 cells. Twist was shown to 
bind the YB-1 promotor and activate transcription (Valsesia-Wittmann et al. 2004; Shiota et al. 
2009). Shiota et al. also described the involvement of programmed cell death protein 4 (PDCD4) in 
this interaction. PDCD4 interacts directly with Twist and leads to reduced cell growth through the 
downregulation of the Twist1 target gene, YB-1 (Shiota et al. 2009). These observations implicate 
YB-1 as positive translational regulator of MYC family proteins and as a protein involved in 
maintaining growth alongside MYC proteins or possibly as an effector. 
 
 
1.3.8. YB-1 SECRETION 
 
Secretion of a protein from a tumor cell exposes it to the hosts immune system, which could result 
in autoantibody production under certain circumstances. In 2009, Frye et al. showed that mesangial 
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and monocytic cells actively secreted YB-1 after inflammatory challenge. Secretion occurred via a 
nonclassical pathway, by-passing the endoplasmic reticulum and Golgi apparatus in the usual 
manner of inflammatory mediators, and YB-1 release required ATP-binding cassette transporters 
and acetylation of two lysine residues in the YB-1 C-terminal domain (Frye et al. 2009). Mitogenic 
and promigratory effects in inflammation, association with outer cell membrane components as 
well as interaction with extracellular Notch-3 receptor domains have been described as effects of 
extracellular YB-1 to date (Rauen et al. 2009). Autoantibodies against YB-1 have also been 
reported in the serum of patients with primary biliary cirrhosis, which is an autoimmune disease 
(Yang et al. 2007). These reports establish proof-of-principle that the YB-1 protein can be secreted 
at least by certain cell types and that it may be autoimmunogenic as a protein in bloodstream. 
 
 
1.4. PROJECT DESIGN AND AIM 
 
NB is a very heterogeneous disease and early detection as well as consequent patient monitoring 
and staging of the disease to prevent patient over- or undertreatment is crucial. Although several 
biological features are currently used for classification, no reliable serum marker protein has been 
described to date. Marker proteins present in patient blood would provide a less invasive and 
effective way to monitor disease. Proteins expressed by the tumor can cause formation of 
autoantibodies. This project aimed to use autoantibodies to identify novel proteins involved in 
development and progression of NB. Protein array analysis was used as an initial step to compare 
antibody expression profiles of NB patients with age- and gender-matched healthy children to 
identify potential tumor-relevant proteins. This group was then narrowed down by choosing 
proteins represented by clones, which were highly abundant on the array or with specificity for a 
certain tumor stage. Additionally, reported connections of the target proteins with aspects of 
cancerogenesis were taken into consideration. The most promising candidate, YB-1, was then 
investigated in cell culture models for NB for its extra- and intracellular abundance in various NB 
cell lines as well as a possible correlation of YB-1 protein expression with known markers of NB, 
such as neurotrophin receptors or NMYC. Since relapse tumors and drug resistance provide a large 
challenge in the treatment of NB patients, downregulation experiments were used to address a 
possible role of YB-1 for proliferation and repair mechanisms and to monitor cytostatic-mediated 
effects on expression as well as cellular distribution via immunoflourescent staining. Co-
immunoprecipitation experiments were then used to identify possible repair-associated binding 
partners of YB-1 in order to gain more insights into the role of YB-1 in NB cells. 
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 2. MATERIALS 
 
2.1. CHEMICALS 
 
Tab. 1: General chemicals 
 Acetic acid  J.T.Baker, Deventer, Netherlands  
 Acetone  Merck, Darmstadt, Germany  
 Albumin ELISA kit Assaypro, St. Charles, USA 
 Chloroform J.T.Baker, Deventer, Netherlands 
 Coomassie brilliant blue R Sigma, Deisenhofen, Germany 
 DMSO  Roth, Karlsruhe, Germany 
 DTT  Invitrogen, Karlsruhe, Germany 
 Dulbecco's Phosphate-Buffered Saline Invitrogen, Karlsruhe, Germany 
 Ethanol  Sigma, Deisenhofen, Germany 
 Glycerin  Merck, Darmstadt, Germany 
 HCl  Merck, Darmstadt, Germany 
 Hoechst 33342 stain Sigma, Deisenhofen, Germany 
 Hydrogen peroxide, 30 % Roth, Karlsruhe, Germany 
 Isopropanol  Roth, Karlsruhe, Germany 
 Isotone Becton-Dickinson, New York, USA  
 Methanol  J.T.Baker, Deventer, Netherlands 
 Mounting medium for fluorescence Vector, Burlingame, USA 
 MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide) 
Roth, Karlsruhe, Germany 
 NaCl Roth, Karlsruhe, Germany 
 NP-40 (nonyl phenoxypolyethoxylethanol) Sigma, Deisenhofen, Germany 
 Paraformaldehyde  Sigma, Deisenhofen, Germany 
 Pepsin Roche Diagnostics, Mannheim, Germany 
 Polyhydroxyethyl starch, 10 % Fresenius, Bad Homburg, Germany 
 Sodium acetate Merck, Darmstadt, Germany 
 Sodium dodecyl sulfate Gerbu, Gaiberg, Germany 
 Sodium- EDTA  Sigma, Deisenhofen, Germany 
 ß-Mercaptoethanol  Sigma, Deisenhofen, Germany 
 Tris base Roth, Karlsruhe, Germany 
 Tris-HCl Sigma, Deisenhofen, Germany 
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 Triton X-100  Merck, Darmstadt, Germany 
 Tween 20  Sigma, Deisenhofen, Germany 
 YB-1 recombinant protein  Biozol, Eching, Germany 
 
 
Tab. 2: Chemicals for western blotting, ELISA and Co-IP 
 BioFX TMB Microwell substrate SurModics, Inc., Eden Prairie, USA 
 BioFX Stop solution SurModics, Inc., Eden Prairie, USA 
 Bradford reagent Roth, Karlsruhe, Germany 
 ECL Plus GE Healthcare, Buckinghamshire, UK 
 Immunoprecipitation kit Santa Cruz Biotechnology, Santa Cruz, USA 
 MOPS (3-(N-morpholino)propanesulfonic acid) Roth, Karlsruhe, Germany 
 Nonfat powdered milk Roth, Karlsruhe, Germany 
 Nuclear extract kit Active Motif, Carlsbad, USA 
 Preclearing matrix F Santa Cruz Biotechnology, Santa Cruz, USA 
 Proteinase inhibitor cocktail Roche Diagnostics, Mannheim, Germany 
 YB-1 human recombinant protein Abnova, Taipei City, Taiwan  
 
 
Tab. 3: Chemicals for cell culture 
 Amphotericin  B PAA, Pasching, Austria 
 Bovine serum albumin  Roth, Karlsruhe, Germany 
 Cisplatin Neocorp AG, Weilheim, Germany 
 FCS Biochrom, Berlin, Germany 
 Geneticine Invitrogen, Karlsruhe, Germany 
 Gentamycin Hexal, Holzkirchen, Germany 
 4-hydroxy-tamoxifen Sigma-Aldrich, Munich, Germany 
 Hyperfect transfection reagence Qiagen, Hilden, Germany 
 Insulin-transferrin-sodium selenite supplement 
(ITS) 
Sigma-Aldrich, Munich, Germany 
 Methylene blue vital stain Serva, Heidelberg, Germany 
 Penicillin / Streptomycin Invitrogen, Karlsruhe, Germany 
 RPMI medium Gibco, Eggenstein, Germany 
 Trypsin/EDTA Invitrogen, Karlsruhe, Germany 
 YB-1 siRNA Qiagen, Hilden, Germany 
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Tab. 4: Chemicals for PCR 
 Agarose Peqlab, Erlangen, Germany 
 Dithiothreitol (DTT) Invitrogen, Karlsruhe, Germany 
 dNTPs Bio-Budget, Krefeld, Germany 
 Go Tag polymerase Promega, Madison, USA 
 MgCl2 , 25 mM Promega, Madison, USA 
 Random primers Invitrogen, Karlsruhe, Germany 
 RNAse H TaKaRa, Otsu, Japan 
 RNeasy Micro kit Qiagen, Hilden, Germany 
 Superscript II reverse transcriptase Invitrogen, Karlsruhe, Germany 
 Trizol reagent  Invitrogen, Karlsruhe, Germany 
 
 
Tab. 5: Primary Antibodies 
 ERCC1, mouse Santa Cruz Biotechnology, Santa Cruz, USA 
 GAPDH, mouse Santa Cruz Biotechnology, Santa Cruz, USA 
 GPI, rabbit Santa Cruz Biotechnology, Santa Cruz, USA 
 HDAC 5, rabbit Santa Cruz Biotechnology, Santa Cruz, USA 
 Histone H3, rabbit Cell Signaling, Danvers, USA 
 Ku80, mouse kindly provided by G. Iliakis, Institute of Medical 
Radiation Biology 
 MAZ, rabbit Santa Cruz Biotechnology, Santa Cruz, USA 
 MYCN, mouse Cell Signaling, Danvers, USA 
 phospho-H2AX (Ser 139), mouse Millipore, Billerica, USA 
 Rad51, rabbit Abcam, Cambridge, USA 
 Transferrin, rabbit Stressgen, Hamburg, Germany 
 XPC, rabbit Santa Cruz Biotechnology, Santa Cruz, USA 
 YB-1, mouse Abnova, Taipei City, Taiwan 
 YB-1, rabbit Epitomics, Burlingame, USA 
 YB-1, rabbit Abcam, Cambridge, USA 
  
 
 
Tab. 6: Secondary  Antibodies 
 biotinylated anti-human, IgG Jackson Immunoresearch, Newmarket, UK 
 Donkey, anti-rabbit IgG-Texas Red Dako, Glostrup, Denmark 
 Goat, anti-mouse IgG-Alexa Flour 594 Invitrogen, Karlsruhe, Germany 
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 Goat, anti-rabbit IgG-HRP Dako, Glostrup, Denmark 
 Goat, anti-mouse IgG Dako, Glostrup, Denmark 
 Rabbit, anti-mouse IgG-HRP Dako, Glostrup, Denmark 
 Streptavidin-Biotin HRP Complex GE Healthcare, Munich, Germany 
 
 
2.2. PLASTICWARE 
 
Tab. 7: General plasticware 
 0.5, 1 and 2 ml safe-lock microcentrifuge tubes  Eppendorf, Hamburg, Germany 
 1-1000 µl filter pipette tips Starlab, Ahrensburg, Germany 
 15 and 50 ml polypropylene screw-cap 
centrifuge tubes  
Greiner, Frickenhausen, Germany 
 5.0 ml combitips Eppendorf, Hamburg, Germany  
 Amicon Ultra-15 centrifugal filter units Millipore, Billerica, USA 
 Gluthatione-coated 96-well plates Therma-Scientific, Rockford, USA 
 Nitrocellulose membrane Whatman, Kent, UK 
 Polyacrylamide precast gels (4-12 %) Invitrogen, Karlsruhe, Germany 
 Single-use PMMA cuvettes Roth, Karlsruhe, Germany 
 Super RX X-Ray film Fujifilm, Tokyo, Japan 
 Whatman blotting paper Whatman, Kent, UK 
 
Tab. 8: Plasticware for cell culture 
 12-, 24- and 96-well culture plates  Corning, NY, USA 
 25 cm2 cell culture flasks  Corning, NY, USA  
 75 cm2 cell culture flasks Greiner, Frickenhausen, Germany 
 Cell culture petri plates Greiner, Frickenhausen, Germany 
 Cell scrapers Greiner, Frickenhausen, Germany 
 Cryopreservation tubes Simport, Beloeil, Canada 
 Sterile pipettes for cell culture  Greiner Frickenhausen, Germany 
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2.3. TECHNICAL EQUIPMENT 
 
Tab. 9: Technical Equipment 
Agarose gel chambers PeqLab, Erlangen, Germany 
Autoclave Systec, Wettenberg, Germany 
Beckman Epics XL FACS  Beckman Coulter, Brea, USA  
Biofuge fresco  Kendro, Langenselbold, Germany 
Blotting chamber BioRad, Herts, UK 
C 1000 thermal cycler BioRad, Herts, UK 
Coulter counter  Beckman Coulter, Brea, USA  
Electrophoresis chambers Invitrogen, Karlsruhe, Germany 
iBlot western blotting system Invitrogen, Karlsruhe, Germany 
KC Junior ELISA reader Biotek, Bad Friedrichshall, Germany 
Leica TCS SP NT confocal microscope Leica, Wetzlar, Germany 
ND-1000 spectrophotometer  Thermo Scientific, Wilmington, USA 
Photometer Eppendorf, Hamburg, Germany 
Precision balance Kern, Balingen, Germany 
Step One Plus real-time PCR system Applied Biosystems, Foster City, USA 
Rotixa 50S  Hettich, Mülheim a.d.Ruhr, Germany 
Thermoblock Roth, Karlsruhe, Germany 
Transilluminator Biometra, Göttingen, Germany 
UVI Chemi Biometra, Göttingen, Germany 
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3. METHODS 
 
3.1. CELL CULTURE 
 
Cell culture was performed under sterile conditions in a laminar flow hood using good sterile 
technique. Cells were cultivated in an incubator at 37°C, 5 % CO2 and humidified air. Established 
neuroblastoma cell lines were cultured in complete medium (RPMI 1640) supplemented with 10 % 
fetal calf serum (FCS), 100 µg/ml penicillin/streptomycin or gentamycin, and Amphotericin B. 
Geneticin (G418, 500 µg/ml) was used for selection of stably transfected cells. A cisplatin-resistant 
subline of SK-N-BE (named SK-N-BEcp here) was kept in complete medium, containing 1.36 µl 
cisplatin per ml medium to maintain resistance. Medium was changed every 2-4 days, and cultures 
were passaged upon 80- 100 % confluency. 
 
The following human neuroblastoma cell lines were used in this dissertation research (detailed 
information can be found in table 10: SK-N-BE as well as the cisplatin-resistant SK-N-BE-cp 
subline, SH-SY5Y as well as the retrovirally transfected SH-SY5Y subclones stably expressing the 
TrkA or TrkB neurotrophin receptors (SY5Y-TrkA or SY5Y-TrkB), SK-N-SH-EP as well as the 
SH-EP-MYCN-ER and Tet-21N subclones, NB69 as well as the retrovirally transfected NB69-
TrkA subclone, IMR-5 as well as the retrovirally transfected IMR-5 TrkA subclone, NGP, Kelly, 
SK-N-SH, WAC2 and SK-N-AS. 
 
Tab. 10: Cell lines used in this dissertation 
Cell line Subclone of MYCN-
amplification
Original reference Provided by 
IMR-5 IMR-32 yes Tumilowicz et al. 1970 Brodeur 
Kelly -- yes Schwab et al. 1983 Brodeur 
NB69 -- no Brodeur et al. 1976 Brodeur 
NGP -- yes Brodeur et al. 1976 Brodeur 
SK-N-SH-EP SK-N-SH no Biedler et al. 1973 Westermann 
SH-SY5Y SK-N-SH no Biedler et al. 1973 Brodeur 
SK-N-BE -- yes Seeger et al. 1977 Centre Leon Berard 
SK-N-AS -- no El-Badry et al. 1989 Brodeur 
Brodeur = Garrett Brodeur, Children´s Hospital of Philadelphia, USA; Centre Leon Berard, Lyon, France; 
Westermann = Frank Westermann, DKFZ, Heidelberg, Germany 
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The SK-N-SH-EP (subsequently named SH-EP) cell line was used for the development of two 
inducible systems. For the tamoxifen-inducible SH-EP-MYCN-ER cell line, cDNA encoding 
MYCN fused to an estrogen-responsive domain (ER) was cloned into the pWZL vector and 
retrovirally transduced into the SH-EP cell line, as described in Schulte et al. 2008.  SH-EP-
MYCN-ER cells were induced with 200 µmol tamoxifen (4-OHT) /ml medium for 72 h. The Tet-
21/N cell line is a conditional, tetracycline-regulated expression system (Lutz et al. 1996). Treating 
Tet-21/N cells with 1 µg tetracycline /ml medium reduced MYCN mRNA expression by at least 15-
fold. 
 
To passage cell lines, the medium was removed with a pasteur pipette, and trypsin was added to the 
cell layer (1 ml for a 25 cm2 cell culture flask, 2 ml for a 75 cm2 cell culture flask) for 3-5 min. 
Trypsinized cells were mixed with complete medium, transferred into a 15 ml tube and centrifuged 
at 800 rpm for 5 min at room temperature. The cell pellet was resuspended in complete medium, 
and cells were seeded into a new flask at a ratio of 1:2 - 1:10, depending on confluency prior to 
splitting and cell line. After trypsinization, cells were counted using a Coulter Counter (Beckman). 
The pellet was resuspended in 5-10 ml complete medium, and 100 µl of the cell suspension was 
diluted with 9.9 ml isotonic saline solution. The cell number was then calculated, and the cell 
suspension diluted accordingly for plating. 
 
Cells were stored in liquid nitrogen for extended periods between experiments. In preparation for 
freezing, cells were trypsinized and centrifuged as described above. The pellet was carefully 
resuspended in 1-2 ml of 90 % FCS and 10 % DMSO and transferred to a cryopreservation tube. 
The cell suspension was slowly cooled and kept in the -80°C freezer or in liquid nitrogen until 
further use. To thaw cells, the cryopreservation tube was quickly warmed to 38 °C and then 
medium was added dropwise to a final volume of 5 ml. The cell suspension was centrifuged as 
described above, and cells seeded into a new flask.  
 
 
3.2. MTT CELL VIABILITY ASSAY  
 
Cell proliferation assays measure the viability and proliferation of cells in vitro under the influence 
of defined external factors. The MTT assay is a colorimetric test, based on the reduction of the 
yellow tetrazolium salt 3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazoliumbromide (MTT) to 
violet formazan crystals via the mitochondrial dehydrogenase in metabolically active cells 
(Mosmann 1983). Absorption of the formazan crystals is measured spectrophotometrically at 570 
nm wavelength against a reference of 630 nm, which MTT does not absorb. Since dehydrogenases 
are only active in living cells, conversion of MTT can be used as a viability assay. Cells were 
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cultured in the presence of MTT in a 96-well plate (MTT stock solution consisted of 5 mg MTT in 
1 ml PBS and was stored in aliquots at – 20 °C). The supernatant was then removed, cells lysed in 
10 % SDS, 5 % acetic acid in DMSO and the 570 nm absorption of the solution was measured on 
an EM800 ELISA-reader (Bio-Tek Instruments). Every experiment was performed at least in 
triplicate. 
 
3.3. RNA EXTRACTION AND CDNA  SYNTHESIS 
 
The Qiagen RNeasy® kit was used to extract total RNA from cells. Cells were lysed in RLT buffer 
(included in the isolation kit) and homogenized by pipetting. The solution was mixed with 70 % 
ethanol in a 1:1 ratio and applied to the RNA-extraction column. RNA bound to the silicagel-
matrix was washed in several steps and then eluted in RNase-free water. Concentration of purified 
RNA was measured photometrically using the absorbance at 260 nm, and RNA samples were 
stored at -80 °C until further use or directly reverse transcribed to cDNA. 
 
For cDNA synthesis, 0.5 - 3 μg total RNA were reverse transcribed using SuperScript II reverse 
transcriptase (Invitrogen), equimolar mixed deoxyribonucleotide triphosphates (dNTPs) and 
random hexamer primers. The reaction mix is shown below, and was initially incubated 5 min at 65 
°C to break RNA secondary structures.  
 
Reaction volume 
 6 µl    
1 µl    
3 µl    
5 µl    
5 µl    
2.5 µl    
1.25 µl 
1.25 µl 
RNA solution (max. 0.5 µg/µl) 
10 mM dNTPs  
random hexamer primer  
5x buffer 
25 mM  MgCl2   
0.1 M  DTT   
RNaseOut  
Superscript II RT polymerase 
 
3.4. POLYMERASE CHAIN REACTION  
 
The polymerase chain reaction (PCR) is used for the specific in vitro amplification of DNA (Mullis 
et al. 1987; Saiki et al. 1988). A temperature-insensitive polymerase and a gene specific pair of 
primers are used.  
 
Primer sequences used in this dissertation were:  
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Primer forward reverse 
GAPDH     ccacccatggcaaattccatggca     tctagacggcaggtcaggtccacc     
YB1     aagtgatggagggtgctgac     tgaccttgggtctcatctcc     
ODC1 cccagcgttggacaaatact     cattgaacgtagaggcagca     
 
A final reaction volume of 20 µl included  4 µl 5 x PCR buffer, 1.2 µl 25mM MgCl2, 0.57 µl 10 
mM dNTPs, 1 µl cDNA, 0,1 µl Taq polymerase and dH2O.  The reaction was performed in 25-30 
cycles after an initial denaturation period. The specific temperature steps were: 
 
Initial denaturation 95 °C 10´ 
Denaturation 94 °C 30 ´´ 
Hybridization x   °C 30 ´´ 
DNA synthesis 72 °C 30 ´´ 
 72 °C 10´ 
   
3.5. SEPARATION AND DETECTION OF NUCLEIC ACIDS 
 
If nucleic acids pass through a matrix in an electric field, they are separated in proportion to their 
molecular weight due to their constant charge: mass ratio. The degree of separation is influenced by 
pore size, depending on the concentration of gel constituent. DNA was separated on 2 % agarose 
gels as previously described (Sambrook 1989). Electrophoresis was performed using Tris-Acetate-
EDTA Buffer (TAE: 0.4 M Tris, 0.01 M EDTA-Na, 0.2 M acetic acid, pH 8.5) as a running buffer, 
and etidium bromide was incorporated in the gel for DNA detection. Etidium bromide integrates 
into nucleic acids and is fluorescent under UV light. 
 
3.6. REAL-TIME PCR 
 
Quantitative real-time PCR was performed on the Applied Biosystems Step One PlusTM real-time 
PCR System. Following the instructions of the manufacturer, the optimal concentration for each 
primer pair and probe were determined. Negative and positive control templates were included for 
each PCR reaction. YB-1 cDNA was amplified using the TaqMan® Gene Expression Assay Nr. 
Hs00898625 (Applied Biosystems). 
 
Components of the real-time PCR reaction mixture were:  
 
TaqMan Fast (20 µl in total) 
TaqMan Fast Universal PCR Master Mix 2 x  10 µl 
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Assay on Demand Gene Expression Assay Mix  20 x  
cDNA dil. in RNA-free H2O (ca. 100 ng)  
1 µl 
9 µl 
 
Taq SYBR Green (20 µl in total)  
SYBR Green PCR Master Mix 2x  
5 pmol forward primer  
5 pmol reverse primer  
cDNA dil. in RNA-free H2O  (ca. 100 ng)  
10 µl 
1 µl 
1 µl 
8 µl 
 
Conditions TaqMan Fast 
95 °C  00:20 
95 °C   00:01 
60 °C  00:20   
40 cycles 
Conditions SYBR Green 
95 °C  10:00 
95 °C   00:15 
60 °C  01:00   
40 cycles 
 
Relative concentrations were calculated for each gene by using a standard curve and crossing 
points. Values for each gene were normalized between samples using the GAPDH housekeeping 
gene.  
 
3.7. TRANSIENT KNOCKDOWN OF YB-1 BY RNAI  
 
RNA interference (RNAi) describes a mechanism for the highly specific silencing of genes using 
short double-stranded RNAs directed against YB-1 mRNA, termed silencing RNAs (Mittal 2004). 
Silencing RNA (siRNA) was directed against YB-1 using the target sequence, 5'-CAG GCG AAG 
GTT CCC ACC TTA-3', and labeled with Alexa Fluor 488 at the 3' end of the sense stand (Qiagen) 
to control for transfection efficiency. 
 
Sense:               r(GGC GAA GGU UCC CAC CUU A)dTdT  
Antisense :   r(UAA GGU GGG AAC CUU CGC C)dTdT 
 
The siRNA was diluted in siRNA suspension buffer (provided by the manufacturer) to a final 
concentration of 20 μM and stored at -20°C. Cells were seeded into 96-well plates and transfected 
when adherent and 60 -70 % confluent. Prior to transfection, 20 pmol siRNA was incubated at 
90°C for 1 min, then at 37 °C for 1 h, then diluted in 100 µl RPMI medium containing 1 µl 
Hyperfect (Qiagen) transfection reagent, and incubated for another 30 min at 37 °C. The 
transfection mix was distributed dropwise into 100 µl culture medium. Fresh culture medium, 
replacing the transfection mix, was added after 24 h. 
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3.8. PREPARATION OF PROTEIN LYSATES FROM CULTURED CELLS 
 
Whole-cell lysates were prepared in RIPA buffer. Medium was removed and cells were washed 
twice with cold PBS before adding 500 µl RIPA buffer (for a 75 cm2 cell culture flask) and 
incubating the flask 1 min on ice. The lysed cells were concentrated to a corner using a cell scraper 
then transferred into a 1.5 ml centrifuge tube. The lysate was incubated for 20 min on ice and then 
centrifuged at 12,000 rpm at 4 °C for 30 min to clear unsolubilized cellular debris from the lysate. 
The supernatant was transferred into a fresh tube, and 24 µl of Roche Complete™ protease 
inhibitor cocktail/ml lysate was added to prevent protein degradation by cellular proteases. 
 
RIPA- Buffer 
Tris-HCl 50 mM 
NaCl 150 mM 
NP-40 1 % 
Sodium Deoxycholate 0.5 % 
SDS 0.1 % 
 
Roche Complete™ protease inhibitor:  
1 tablet was dissolved in 3 ml sterile ddH20 and stored at -20 ° for up to 4 weeks 
 
 
3.9. PREPARATION OF MEDIUM CONDITIONED BY NEUROBLASTOMA CELL 
CULTURES 
 
Medium was collected in which NB cell lines had been cultured to detect proteins secreted by the 
cultured cells. In order to reduce the mitogen background present in fetal calf serum, cell lines were 
cultured in serum-free, supplemented medium for conditioned medium (CM) collection. Cells were 
plated at 30-50 % confluency in complete medium. When cultures reached approximately 60 % 
confluency, the complete medium was removed, cells were washed three times with RPMI medium 
containing no supplements and RPMI supplemented with 1 % ITS and 0.001 % hydrocortisone was 
added (15 ml for a 75 cm2 cell culture flask). After 72 h, the medium was transferred into a 50 ml 
centrifuge tube, 24 µl Complete™ proteinase inhibitor cocktail (Roche) was added per ml and the 
CM was centrifuged at 1000 rpm and 4 °C for 10 min to remove cellular debris. The cleared CM 
was sterile filtered and stored at -80 °C. CM was concentrated using Amicon Ultra-15 Centrifugal 
Filter Units (Millipore), centrifuged at 1500-3000 rpm until an approx. 100-fold concentration was 
achieved. Concentrated CM was transferred into 1.5 ml tubes and stored at -80 °C. 
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3.10. CROSSLINKING OF PROTEINS IN CONDITIONED MEDIUM 
 
Conditioned medium was prepared as described above and 1 ml was mixed with 5 µl 25 % 
gluteraldehyde then incubated 5 min at 4 °C. The crosslinking reaction was stopped by adding 100 
µl 1M Tris-HCl. Crosslinked CM was either used directly or stored at -80 °C. 
 
 
 
3.11. WESTERN BLOTTING  
 
Cells were washed three times with PBS and lysed in cold RIPA buffer containing Complete™ 
Protease Inhibitor Cocktail (Roche). Protein concentration was measured using the Bradford 
photometric assay, then lysate containing 5 µg protein was separated in a NuPAGE® BisTRIS 4-12 
% polyacrylamide gradient gel (Invitrogen), electroblotted onto a nitrocellulose membrane and 
blocked with 5 % milk powder in PBS containing 0.02 % Tween-20 (PBS-T). The primary 
antibody was diluted in the blocking solution and incubated with the membrane for 16 h at 4 °C. 
After three washes with PBS-T, the blot was incubated with the secondary antibody in blocking 
solution for 1 h at room temperature. Concentrations varied for the different antibodies, and are 
listed in the table below. Immune complexes were detected via the light emitted by the reaction of 
the horseradish-peroxidase enzyme conjugated to the secondary antibody with the Amersham ECL 
Plus™ Western Blotting Detection Reagent (GE Healthcare), and visualized on either Kodak 
Medical x-ray film or by the BioDocAnalyze system (Biometra). The GAPDH housekeeping 
enzyme was analysed on the same immunoblots to allow normalization for target protein amounts 
between cell lysates. Immune complexes from the target protein detection were removed from the 
membrane by stripping for 20 min at 65 °C before GAPDH detection. 
 
Tab. 11: Antibodies and corresponding dilutions used in this dissertation project 
ERCC1, mouse (Santa Cruz Biotechnology) 1:2000 
GAPDH, mouse (Santa Cruz Biotechnology) 1:2000 
GPI, rabbit (Santa Cruz Biotechnology) 1:2000 
Ku80, mouse (kindly provided by G. Iliakis, Institute of Med. Radiation Biology) 1:200 
MYCN, mouse (Cell Signaling) 1:1000 
Rad51, rabbit (Abcam) 1:1000 
Transferrin, rabbit (Stressgen) 1:4000 
XPC, rabbit (Santa Cruz Biotechnology) 1:2000 
YB-1, mouse (Abnova) 1:2000 
YB-1, rabbit (Epitomics) 1:2000 
YB-1, rabbit (Abcam) 1:2000 
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Goat, anti-rabbit IgG-HRP (Dako) 1:2000 
Rabbit, anti-mouse IgG-HRP (Dako) 1:2000 
Streptavidin-Biotin HRP Complex (GE Healthcare) 1:2000 
 
MOPS-SDS running buffer (20 x)  
MOPS 104.6 g 
Tris base 60.6 g 
SDS 10.0 g 
EDTA 3.0 g 
ddH20 to 500 ml 
 
10 x transfer buffer 
Tris base 30.3 g 
Glycine 144.0 g 
ddH20 to 1 l 
 
Stripping buffer  
Tris-HCl 9.47 g 
Tris base 0.289 g 
SDS 20.0 g 
ddH20 to 1 l 
β-mercaptoethanol was added to a final concentration of 0.7 %  immediately before use 
 
 
3.12. CO- IMMUNOPRECIPITATION 
 
Whole-cell lysates were prepared in RIPA buffer and were precleared by incubation for 16 h at 4 
°C with Preclearing Matrix F (ExactaCruz) to remove proteins that unspecifically bind the co-
immnuoprecipitation matrix. The suspension was then centrifuged to pellet the matrix, and the 
supernatant was used for co-immunoprecipitation (Co-IP) of YB-1 with binding partners. 
Formation of the antibody-IP matrix complex was performed according to the manufacturer’s 
instructions. The matrix was mixed with the precleared cell lysate and incubated on a rotary shaker 
overnight at 4 °C. The complex was pelleted by centrifugation at 10,000 rpm for 30 sec at 4 °C.  
The supernatant was removed and the matrix washed twice with RIPA and then once with PBS, 
each washing step was performed for 15 min on a rotary shaker at 4 °C. Proteins bound to the 
matrix were eluted in 15 µl loading buffer for SDS-PAGE, of which 5 µl was loaded per lane and 
separated on a NuPAGE® BisTRIS 4-12 % polyacrylamide gradient gel, then the presence of YB-
38 
 
1, Ku80, Rad51 and XPC was analyzed on western blots. Aliquots of the supernatant at each step 
were also analyzed by western blotting to establish the co-IP protocol and as controls for the co-IP. 
 
 
3.13. YB- 1 REVERSE ELISA 
 
An ELISA-based detection method was developed to detect autoantibodies against YB-1 in patient 
sera using immobilized YB-1 protein and photometric quantification of the immune complex. All 
incubation steps were carried out on a rotary shaker and the indicated temperature. To immobilize 
YB-1 protein, 30 µl of a 0.01 µg/ml solution of recombinant GST-tagged YB-1 protein in 0.05 M 
Tris-HCl was incubated per well of a gluthatione-coated 96-well plate for 16 h at 4 °C to allow 
binding of the GST-tag to the glutathione-coated surface. Unbound protein was removed in three 
rounds of washing with 200 µl PBS-T-05 (PBS containing 0.05 % Tween-20) per well. PBS-T-05 
containing 5 % BSA was used to block unspecific binding for 7 h at RT, after which wells were 
washed twice with 200 µl PBS-T-05, then 24 µl blocking solution mixed with 3 µl patient serum 
were transferred to the wells and incubated for 16 h at 4 °C.  Subsequently, wells were washed 
once with PBS-T-05 to remove unbound proteins. Biotinylated α-human IgG antibody (Jackson 
Immunoresearch) was diluted 1:100,000 in blocking solution, and 40 µl was added to each well and 
incubated for 3 h at room temperature. Wells were washed once with 200 µl PBS-T-05 then 1µl of 
streptavidin-biotin-HRP complex (GE Healthcare) diluted 1:2000 in blocking solution was added 
to each well and incubated for 1 h at room temperature. Wells were subsequently washed 3 x with 
PBS-T-05 prior to immune complex detection using 100 µl BioFX® TMB Microwell Substrate 
(SurModics, Inc.) per well. The plate was incubated for 10-60 min until sufficient color change 
occurred, and the reaction was stopped and fixed by adding 100 µl BioFX® Stop Solution 
(SurModics, Inc.). The absorbance at 450 nm was measured for the reverse ELISA plate wells. 
Serum from a healthy adult volunteer was used as a reference to standardize individual experiments 
and allow comparison across experiments. Control serum was included on every plate, and set to 
100 units. For normalization of YB-1 antibody concentrations across different patient serum 
samples, total protein concentration in the patient sera was either estimated based on the intensity 
of a defined band from 1 µl serum separated on NuPAGE® BisTRIS 4-12 % polyacrylamide 
gradient gels, total protein in the gels were stained with Coomassie Brilliant Blue R, or based on 
the albumin concentration determined by the AssayMax Human Albumin ELISA Kit (Assaypro).  
 
 
3.14. QUANTIFICATION OF DOUBLE-STRAND BREAKS VIA GAMMA-H2AX 
 
The histone variant H2AX is phosphorylated at serine 139 in response to DNA double-strand 
breaks, leading to the formation of γ-H2AX foci at the damaged sites. Phosphorylation is mediated 
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by activation of the phosphatidylinositol-3-OH-kinase-like family of protein kinases, DNA-PKcs, 
ATM and ATR, and is used as a connection point for accumulation of central components of the 
signal cascade initiated by the DNA damage (Rogakou et al. 1998). DNA double-strand breaks 
were quantified by immuncytochemically staining NB cells for γ-H2AX foci and counting them in 
a total number of 100 cells per sample. Cells were grown in complete medium on sterile coverslips 
in a 24-well plate. Transfection with siRNA against YB-1 was performed at 70 % confluency as 
described above. Medium was changed 24 h after transfection. Cells were then left untreated or 
irradiated with gamma radiation at 1 Grey 48 h after transfection, depending on the experiment. For 
γ-H2AX staining, cells were washed with PBS, fixed on coverslips with 4 % parafomaldehyde for 
10 min at room temperature, then washed three times with PBS and either stored at 4 °C or 
processed immediately. All incubations were conducted at room temperature unless otherwise 
stated. Cells were permeabilized in PBS containing 0.2 % Tritron X-100 and 1 % BSA for 10 min 
on ice, then washed again with PBS containing 1 % BSA for 2 x 5 min and incubated in blocking 
solution (PBS containing 3 % BSA and 0.2 M glycine) for 1 h. A polyclonal antibody against 
phospho-H2AX (Ser 139, Millipore) was diluted 1:200 in PBS-T-05 containing 1 % BSA for 1 h.  
Unspecific antibody binding was removed by a 1 h washing step in PBS-T-05 containing 1 % BSA. 
Alexa Flour 594-labeled Molecular Probes® anti-mouse IgG (Invitrogen) was diluted 1:2000 in 
PBS containing 0.5 % goat serum and incubated with the cells for 1 h. Cells were washed twice in 
PBS, then nuclei were counterstained with a 250 ng/ml DAPI (H33342). After washing another 
time with PBS, cells were mounted onto microscope slides using Vectashield® Flourescent 
Mounting Medium (Vector Laboratories) and stored at 4 °C until observation.  
 
 
3.15. IMMUNOCYTOCHEMISTRY 
 
Cells were grown in complete medium on sterile coverslips in 24-well plates for YB-1 
immunocytochemistry. When cultures reached 60 % confluency, cells were washed with PBS, 
fixed on coverslips with 4 % parafomaldehyde for 10 min at room temperature, then washed three 
times with PBS and either stored at 4 °C or processed immediately. All incubations were conducted 
at room temperature unless otherwise stated. Cells were permeabilized in PBS containing 0.2 % 
Tritron X-100 and 1 % BSA for 10 min on ice then washed twice for 5 min with PBS containing 1 
% BSA. A demasking step was performed next to allow better binding of the antibody to 
intracellular proteins. The coverslips were incubated 5 min in saline-sodium citrate (SSC) buffer in 
a steam bath, then slowly cooled to room temperature 3 times in succession using fresh SSC buffer 
each time. To prevent unspecific binding, the coverslips were then incubated in blocking solution 
for 1 h. The primary antibody targeting YB-1 (Abcam) was diluted 1:100 in PBS-T-05 containing 1 
% BSA, and cells were incubated for 1 h.  Unspecific antibody binding was removed by a 1 h 
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washing step in PBS-T-05 containing 1 % BSA before incubation with the secondary antibody, 
donkey anti-rabbit IgG labeled with Texas Red (Dako), diluted 1:200 in PBS for 1 h. Cells were 
washed twice in PBS, then nuclei were counterstained in a 250 ng/ml solution of DAPI (H33342) 
in PBS before washing again once with PBS. Coverslips were mounted onto microscope slides 
using Vectashield® Flourescent Mounting Medium (Vector Laboratories) and stored at 4 °C.  
 
20 x Saline-sodium citrate (SSC) buffer 
NaCl 175.3 g 
Na3Citrate x 2H2O 88.2 g 
ddH2O to 1 l 
 
 
3.16. ADDUCT AK 
 
SK-N-BE and SK-N-BEcp cells were transfected with siRNA targeting YB-1, then pulse-treated 
with cisplatin for 4 h (SK-N-BE cells with 12.5 µg/ml and SK-N-BEcp with 17.5 µg/ml) 48 h after 
transfection, before transferring to fresh medium without cisplatin and an additional 24 h of culture. 
After trypsinization and washing, cells were pelleted by centrifugation, resuspended in PBS 
containing 25% starch solution and spotted onto precoated microscopic slides. The following steps 
were performed in the Institute for Cell Biology, University Hospital Essen (Thomale Group). 
After air drying the slides, cells were fixed in methanol at −20°C for 12 h and then rehydrated in 
PBS for 10 min at 25° C. Cellular RNA was digested by RNase treatment (RNase A, 200 µg/ml; 
RNase T1, 50 U/ml in PBS; 100 µl per slide) for 1 h at 37°C in a humidified chamber. Each of the 
steps was followed by washing with PBS. Nuclear DNA was partly denatured by mild treatment 
with alkali (70 mM NaOH, 140 mM NaCl, 40% methanol v/v; 5 min at 0° C) and cellular proteins 
were removed by a two-step proteolytic procedure: Samples were first digested with prewarmed 
pepsin (Roche; 200 µg/ml;) for 5 min at 37°C, and then with prewarmed proteinase K (2 µg/ml in 
20 mM Tris–HCl, 2 mM CaCl2, pH 7.5) for 5 min at 37°C. After blocking with casein (1% in PBS) 
for 30 min at 25°C, slides were incubated with anti-Pt-DNA antibodies (in-house antibody, 0.1 
µg/ml in PBS containing 1% casein and 200 µg of sonicated calf thymus DNA/ml; 2 h; 37°C). 
After washing with 0.05% Tween 20 in PBS for 2 min at 25°C, three-step sandwich 
immunostaining was performed by subsequent incubation with: (i) FITC-labeled goat anti-rat Ig 
(Dianova, Hamburg, Germany; 6.5 µg/ml in PBS, 1% casein; 45 min; 37°C), (ii) ALEXA FLUOR 
488-labeled rabbit anti-FITC (5 µg/ml in PBS, 1% casein; 45 min at 37°C; Molecular Probes) and 
(iii) ALEXA FLUOR 488 goat anti-rabbit IgG (5 µg/ml in PBS, 1% casein; 45 min, 37°C; 
Molecular Probes). Nuclear DNA was counterstained with DAPI (1µg/ml in PBS) for 30 min at 
25°C, and cells were mounted in Vectashield mounting medium. Position, area and intensities of 
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signals from individual cell nuclei were visualized by fluorescence microscopy, and recorded using 
an image analysis system. Antibody-derived signals were normalized for the actual DNA content of 
a given cell and expressed as arbitrary fluorescence units (AFU). 
 
 
3.17.  CHIP-CHIP ANALYSIS 
 
Chromatin immunoprecipitation (ChIP) was performed to detect binding of MYCN/cMYC proteins 
to target gene promoters. ChIP was performed in the laboratory of F. Westermann (DKFZ, 
Heidelberg), and a shortened version of the original protocol is described here. Cells were treated 
with 1 % formaldehyde for 10 min at RT to crosslink DNA with bound proteins, then incubated 
with 125 mM glycine for 5 min to inactivate formaldehyde within the cells. Cells were washed 
with 5 ml PBS, scraped off and pooled in 2 ml PBS containing protease inhibitors. After pelleting, 
nuclei were isolated from cells in a step-wise procedure. Cells were flash frozen in nitrogen, 
incubated in lysis buffer then manually disrupted using a Dounce homogenizer. Nuclei were 
washed, then sonicated, and DNA amount and fragment size were assessed on 2% agarose gels. For 
preclearing, chromatin was treated with RNase A and proteinase K, centrifuged at 16,000 g at 4 °C 
for 10 min, then supernatant was incubated with 200µl 1:1 protein A/protein G-coated sepharose 
beads. After preclearing, chromatin amount was measured by NanoDrop. ChIP was performed 
using the precleared chromatin-protein suspension on the magnetic substrate, Dynabeads. 
Dynabeads were first incubated in 250 µl block solution and 10 µg corresponding antibody 
overnight at 4 °C on a rolling mixer, then washed 3 times with 1 ml block solution and resuspended 
in 100 µl block solution. All components for immunoprecipitation were transferred to a pre-cooled 
15 ml polyethylene tube, adding the DNA and Dynabeads last. The immunoprecipitation mixture 
(130 µl 10 % Triton X-100, 26 µl 50x protease inhibitor, 13µl 10% Na-deoxycholate, 131 µl water, 
100 µl Dynabeads and 400 µg DNA, adjusted to 1300 µl with LB3) was incubated overnight at 4 
°C on a rolling mixer. Dynabeads were washed, residual buffer removed, and 210 µl elution buffer 
was added then incubated at a 65 °C for 30 min. Dynabeads were centrifuged at 16,000 g for 1 min, 
and 200 µl of the supernatant was transferred to a new tube. All samples were incubated at 65 °C 
for at least 6 h for reverse of crosslinking. To dilute the SDS in the elution buffer, 200 µl of TE 
buffer was added to the samples. DNA was precipitated via phenol–chloroform extraction, washed 
with 500 µl 80% ethanol and diluted in 12.3 µl ultrapure water then stored at -80 °C. Amplification 
of the immunoprecipitated DNA is necessary for later microarray analysis, and was performed 
using the WGA kit (Sigma). Input concentration was quantified by UV absorption and adjusted to 1 
ng/µl, whereas, immunoprecipitated DNA was not diluted. Fragmentation buffer at a 10x 
concentration (1 µl) was added to 10 µl of DNA and incubated at 95 °C for 4 min. To each sample, 
2 µl of 1x library preparation buffer and 1 µl of library stabilization solution were added. Samples 
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were incubated at 95 °C for 2 min, cooled on ice, then 1 µl library preparation enzyme was added 
before incubating at 16 °C for 20 min, 24 °C for 20 min, 37 °C for 20 min and 75 °C for 5 min. 
Amplification master mix was added to the reaction (7.5 µl of 10x amplification master mix, 47.5 
µl water, 5 µl of WGA DNA Polymerase), vortexed thoroughly, centrifuged and put into the 
thermocycler (95 °C for 3 min; 14 cycles: 94 °C for 15 s, 65 °C for 5 min). DNA concentration was 
measured and all samples were normalized to 100 ng/μL. For a 2-color microarray input, the input 
DNA was labeled with Cy3 and the immunoprecipitated sample with Cy5 fluorescent dyes. 
Components of the BioPrime CGH labeling kit (Invitrogen) were joined in a 0.5 ml tube and 
incubated at 95 °C for 5 min (2 µg amplified sample DNA, 35 µl random primer, 20µl ddH2O). 
The mixture was put on ice immediately and 13 µl of the labeling mastermix (8.2 μl 10x dUTP 
nucleotide mix, 1.5 μl Cy5- or Cy3-dUTP, 1.5 μl Klenow, 1.8 μL ddH2O) was added. The samples 
were incubated for 3 h, 37 °C, then 9 µl of stop buffer was added. Labeled fragments were isolated 
on the columns provided in the kit, according to the manufacture´s manual. Cy-label and total DNA 
yield was measured by NanoDrop. Cy5- and Cy3-labeled samples were combined in a 1.5 ml tube 
(5 µg input DNA, 5 µg immunoprecipitated DNA, 150 µl ddH2O). 50 µl Cot-1 DNA (1 mg/ml), 50 
µl blocking agent and 250 µl hybridization buffer from the Oligo aCGH/ChIP-on-chip 
Hybridization Kit (Agilent) were added. The samples were mixed, incubated at 95 °C for 3 min and 
37 °C for 30 min, then collected by centrifugation then used to probe the Agilent Human Promoter 
Microarray. Arrays were incubated in a rotating hybridization oven at 65 °C and 10 rpm for 40 h. 
The array slide was washed with Oligo aCGH/ChIP-on-chip wash buffers prior to scanning on a 
GenePix® 4000B scanner (Molecular Devices). 
 
 
3.18. ACQUISITION OF SERUM SAMPLES 
 
Serum was obtained from NB patients at the time of and for the purpose of diagnosis. All patients 
were included in German NB trials, for which patient/parent consent was obtained. Retrospectively 
collected serum was provided by the serum-bank in Göttingen, Germany. Serum from healthy 
children was obtained from stored samples from being tested for unrelated problems, which were 
deemed healthy, or before acting as bone marrow donors. Only serum obtained from healthy adult 
volunteers was obtained solely for the purpose of this study. Controls serum samples were chosen 
from those available to be age- and gender-matched to those from NB patients.  
 
 
3.19. FETAL BRAIN ARRAY 
 
The search for autoantibodies in patient serum using the fetal brain protein array was performed by 
the RZPD institute in Heidelberg, Germany. The protein array contained 4438 proteins, printed in 
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duplicate onto PVDF membranes. Printed proteins were derived from expression verified, full-
length or shorter cDNA clones from a human fetal brain cDNA library. Detection was carried out 
using either a Cy3- or Cy5-labeled IgM antibody against human IgG. Results of the separate runs 
were obtain by laser scanning and then compared pair-wise between control and disease sera. The 
data generated from these screens was analyzed by P2b to identify autoantibodies to possible stage-
specific marker proteins in pooled serum. Patient sera were pooled according to their NB stage for 
array analysis, and each serum pool was composed of serum from 8-10 individual patients.  
 
 
3.20. STATISTICAL ANALYSIS 
 
Measurement of band intensity on Coomassie brilliant blue R stained gels, ethidium bromide- 
stained agarose gels containing PCR products and western blots was done using the Biometra 
BioDocAnalyze software. The GraphPad Prism 5 program was used for statistical analysis, 
including the calculation of significance for reverse ELISA, TrkA expression in NB cells and 
quantification of double strand breaks by unpaired two tailed t-test (95 % confidence interval). 
Data of ELISAs, TrkA expression, proliferation assays, double strand break quantification and YB-
1 protein expression following cisplatin treatment is shown as mean with standard deviation. 
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4 RESULTS 
 
4.1 USING AUTOANTIBODIES IN NEUROBLASTOMA PATIENT SERUM TO IDENTIFY 
TUMOR MARKERS 
 
4.1.1 Autoantibodies were detected in NB patient sera via a protein array 
Differentially expressed proteins by tumor and healthy cells or between cells from NBs of different 
stages may be indicative of the presence of the tumor or different states of the disease, and could, in 
certain cases, induce the formation of autoantibodies against the protein by patient’s immune 
system. It has been shown that cancer patients occasionally show immune responses to self-
proteins expressed by their tumors (Anderson et al. 2005). Antibody proteins generally have a long 
half-life in serum, indicating that they should also be highly stable molecules in stored blood and 
serum samples. Specific antibodies are also relatively easy to measure using current 
immunologically based methods, making them potentially useful as clinical biomarkers for 
detection or monitoring of cancer and cancer treatment. More importantly, antibodies can be 
generated from very slight changes in overall expression of a tumor-related or disease stage-related 
protein, making them potentially useful for identifying proteins important in these processes. A 
protein array of 4438 proteins from a human fetal brain cDNA library (Fig. 5a) was used to detect 
NB-specific or NB stage-specific autoantibodies in pooled patient serum. Array membranes were 
incubated with pooled sera from patients with stage 1, 4 or 4S NB, or from healthy age- and 
gender-matched children. When a signal was detected for both duplicate spots of the protein from 
the same cDNA clone, the protein was designated as being recognized by an autoantibody from 
that serum pool. The defined order in which clones were spotted onto the membrane allowed 
subsequent identification of corresponding positive clones via location of the positive binding 
signal (Fig.5b). 
a)       b) 
  
Fig. 5: The fetal brain protein array used for the detection of autoantibodies a) Schematic overview of the 
detection method. b) Image of the readout of positive clones from the protein array. Protein array screening 
was conducted by the Deutsche Ressourcenzentrum für Genomforschung (RZPD, Heidelberg). 
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Positive signals from groups were compared to yield a relative picture for the identification of 
autoantibodies produced by a specific group. In this pairwise comparison, NB patient groups were 
compared with each other or to healthy controls. Each pairwise comparison generated a list of 
clones, whose protein products were bound by patient autoantibodies relative to the group to which 
it was being compared. These protein targets were ranked according to the significance of the 
relative difference between the two groups that were compared. Lists were generated, which 
showed the top 20 clones of the comparisons between specific patient subgroups. Proteins against 
which autoantibodies were detected for a specific NB stage within a specific pairwise comparison 
were sorted by function and are shown as pie charts in Fig. 6.  Among these were intracellular as 
well as cell surface proteins. A large fraction of the proteins detected are of unknown function 
(grey, Fig.6) because either unambiguous sequence data was unavailable for many of the clones on 
the protein array or the sequence data did not depict a single identifiable protein.  
 
  
 
Fig. 6: Graphical breakdown of the 20 most significant targets of autoantibodies detected according to patient 
subgroup. Protein functions and/or identities were used for the top 20 targets of the pairwise comparison 
indicated above each pie chart. Data was analyzed in cooperation with M. Zapatka (DKFZ Dept. of 
Theorethical Bioinformatics, Heidelberg). 
 
Five protein targets of patient autoantibodies were chosen for further investigation (Table 3). 
Various factors were considered for this decision, including the abundance of positive clones 
recognized on the protein array or a specificity for a certain tumor stage. Autoantibodies against the 
MAZ protein were, for example, detected in serum from NB patients but not healthy controls. 
Reported connections of the target proteins with aspects of cancerogenesis were also taken into 
46 
 
consideration. Autoantibodies to the YB-1 protein were not only detected in serum from patients 
with stage 1, 4 and 4S NB, but also recognized several independent clones expressing different 
areas of the YB-1 protein, making it an interesting target for further research. 
 
Table 12: Autoantibody target proteins selected for further investigation 
Autoantibody Target Protein Specifically Detected in Sera from:  
Glucose-6-phosphate isomerase (GPI) stage 1 NB patients 
Myc-associated zinc finger protein (MAZ) all NB patients, compared to healthy controls 
Heat-shock protein 90 (Hsp90)  stage 4S NB patients 
Histone deacetylase 5 (HDAC5)  stage 4S NB patients 
Y-box binding protein 1 (YB-1) all NB patients, compared to healthy controls 
 
 
4.1.2 The GPI protein is present in conditioned media of neuroblastoma cells  
Glucose-6-phosphate isomerase (GPI) was originally described as a housekeeping enzyme in the 
Embden-Meyerhof pathway (Watanabe et al. 1996). It was also independently identified as both 
neuroleukin (NLK) and autocrine motility factor (AMF), extracellular factors that promote tumor 
progression and metastasis as well as cell migration and invasion (Yanagawa et al. 2004: Torimura 
et al. 2001). This link makes GPI an interesting target for NB research. Autoantibodies against GPI 
were detected in pooled sera from stage 1 NB patients on the protein array. This is not the first case 
where patient autoantibodies against GPI have been detected. They have also been reported in 
patients with rheumatoid arthritis (Schaller, 2001). In this project, the next step was to check 
whether GPI was also present in NB sera. Western blot analysis confirmed ubiquitous strong 
expression of GPI in a panel of NB cell lines frequently used in the laboratory (data not shown), as 
was expected for a house-keeping enzyme. To assess whether GPI could also be secreted from NB 
cells, the cell lines were maintained in serum-free medium for three days to reduce proteins from 
the calf serum, and this conditioned medium was collected and sterile filtered. The conditioned 
medium was concentrated, then analyzed on western blots. GPI was detected at its predicted size of 
63 kDa in conditioned medium from SK-N-BE, IMR5, SY5Y, NGP, NB69 SK-N-AS and Kelly 
cells (Fig. 7), confirming the extracellular presence of GPI in all tested NB cell culture models. 
Since neurotrophin receptors play a crucial role in the development of NB, an SH-SY5Y cell 
model, stably transfected with either TrkA or TrkB was also included in the panel to assess whether 
neurotrophin receptor overexpression altered extracellular GPI levels. Higher amounts of GPI were 
detected in conditioned medium from TrkA overexpressing cells, whereas lower amounts of GPI 
were detected in medium conditioned by TrkB-transfected cells compared to the parental cell line. 
Since NBs often develop resistance to the chemotherapeutic agent used in therapy, a cisplatin-
resistent cell line was also included in the panel to test for a possible correlation of resistance with 
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extracellular GPI. Higher amounts of GPI were also detected in conditioned medium from 
cisplatin-resistant SK-N-BE cells, compared to the parental cell line. 
 
 
Fig. 7: GPI protein in conditioned media from neuroblastoma cell lines and expression cell models for Trk 
receptor proteins. The cells were cultured in serum-free medium for three days. The medium was removed, 
concentrated using Amicon© 5 kDa cut-off centrifugal concentration units and GPI protein was analyzed on 
western blots. Total protein content in the conditioned media was determined on SDS-PAGE via staining 
with coomassie brilliant blue R and used as a loading control.  
 
In addition to the 63 kDa band, a second band of approximately 130 kDa was detected. GPI is 
known to dimerize (Sun et al. 1999), and the dimeric form has been reported to be approx. 130 
kDa. However, since proteins separated using SDS-PAGE are applied to the gel and run under 
denaturing conditions, any secondary structures not connected by covelent bonds are interrupted. 
Therefore, if the dimer is linked by weaker interactions, only the monomeric form should have 
been observed. For the purpose of identifying the actual position of a GPI dimer on western blot, 
freshly prepared conditioned medium was cross-linked via glutaraldehyde to conserve any 
secondary structures and to preserve existing multimers. It was then concentrated using Amicon© 
concentration units and analyzed by western blotting for the presence of GPI (Fig. 8). While the 
concentrated but otherwise untreated conditioned medium contained GPI at both 63 and 130 kDa, 
the glutaraldehyde cross-linked sample showed only a single band at 130 kDa, showing that to be 
the actual position of the dimer.  
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Fig. 8: Conditioned medium from NGP cells was concentrated by centrifugation through Amicon© 
concentration units and analyzed by western blotting with an antibody targeting GPI. The left lane shows the 
GPI protein in concentrated but otherwise untreated CM, the right lane shows GPI in the conditioned medium 
treated with glutaraldehyde before concentration to crosslink existing non-covalently bound multimers. 
 
This experiment suggested that conditioned medium contained the dimeric form of GPI. The 
persistence of the dimer during denaturing SDS-PAGE could be due to a mechanical formation of 
bonds or steric conformations that formed during the concentration process. New conditioned 
medium was prepared and concentrated via evaporation at 39 °C instead of Amicon© concentration 
units. Only the 63 kDa GPI monomers were detected in medium concentrated by evaporation (data 
not shown), confirming that the persistant dimer formation was artefact of the concentration 
process. Taken together, GPI was detected in various amounts in conditioned medium from all NB 
cell lines in the panel examined. Extracellular GPI was elevated in cisplatin-resistant and TrkA-
overexpressing cells compared to the parental cell lines. At least some of the extracellular GPI was 
present as dimers, the active form of the protein (Yanagawa et al. 2005), other than the persistant 
dimers produced as an artifact of concentration. Confirmation of extracellular GPI in NB cell 
cultures and published reports associating extracellular GPI with migration and invasion 
(Yanagawa et al. 2004; Torimura et al. 2001) indicated GPI could be an interesting target for future 
research. 
 
4.1.3 YB-1 is expressed in neuroblastoma cells  
YB-1 has also been shown to be involved in different aspects of tumorigenesis, as described in the 
introduction, making it an interesting candidate. Autoantibodies directed against YB-1 were 
detected in patient sera from all NB stages on the protein array, and these autoantibodies 
recognized different regions of the YB-1 protein. As the next step, YB-1 expression was evaluated 
in a panel of NB cell lines. The panel included cell lines with a single copy of MYCN as well as 
MYCN-amplified cell lines to represent both important NB phenotypic subgroups. Whole-cell 
extracts were prepared in RIPA buffer, and YB-1 was detected via western blotting (Fig. 9), YB-1 
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was expressed in similar amounts by all cell lines in the panel. No significant correlation between 
the amounts of YB-1 protein expression and MYCN status was observed  
 
 
Fig. 9: Whole-cell extracts of NB cell lines were prepared in RIPA buffer and analyzed by western blotting 
using an antibody to YB-1. GAPDH was used as loading control. Single-copy and MYCN-amplified cell lines 
were included in the panel, a list of MYCN amplified cells can be found in the method section. 
 
 
4.1.4 Use of a reverse ELISA to detect and quantify YB-1 autoantibodies in patient serum 
 
4.1.4.1  Development of a YB-1 reverse ELISA 
 
To verify the presence of autoantibodies against YB-1 in NB patient sera on an independent 
technological platform and to create a way to quantify YB-1 autoantibodies in serum samples from 
individual patients, a reverse ELISA was developed. Glutathione-coated 96-well ELISA plates and 
recombinant YB-1 protein (Abnova) N-terminally tagged with glutathione S-transferase (GST) 
were used. ELISA wells were incubated with 30 µl of 0.05 M Tris-HCl containing 0.3 ng GST-
tagged YB-1 protein as described in the materials and methods section (section 3.13). Through 
binding of the GST-tag to the glutathione on the well floor, the plates were evenly coated with YB-
1 protein via a short tether and allowing better access to the protein for antibody binding. Unbound 
protein was removed in three rounds of washing and blocking of unspecific binding, as described in 
the method section.  
 
4.1.4.2 Evaluation of the YB-1 reverse ELISA 
In the process of developing the assay, its sensitivity was tested by addition of spiked-in amounts 
of murine YB-1 antibody (Abnova). The antibody was added to serum of healthy adults at a 
dilution of 1:100, then serial dilutions were performed with adult serum to reach YB-1 antibody 
dilution of 1:2000. For each well, 1 µl of spike-in control serum dilution was then mixed with 29 µl 
of blocking solution to a total volume of 30 µl yielding final dilutions of 1:3000 up to 1:60,000. 
GST-tagged Galectin-1 protein in a final dilution of 1:3000 was used as a negative control to 
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exclude unspecific binding. Detection of bound antibody was achieved via a biotin-coupled 
polyclonal goat anti-mouse antibody (1:4000, Dako), followed by streptavidin-biotin complex 
(1:1000, GE Healthcare). Incubation and washing steps were performed as described in section 
3.13. Quantification followed addition of 100 µl BioFX® TMB Microwell Substrate (SurModics 
Inc.), which was converted by the horseradish peroxidase in the immune complexes. The 
conversion was stopped at 35 min, using 100 µl BioFX® Stop Solution (SurModics Inc.). The 
graph shows a linear correlation of light emission and amounts of spiked-in YB-1 antibody. Strong 
signal detection was possible up to a dilution of 1:45,000 and the negative control showed very low 
unspecific binding. This experiment showed the possibility to detect and quantify low amounts of 
YB-1 antibody using the reverse ELISA.  
 
Fig. 10: Reverse ELISA detection of serum of healthy adults with spiked-in murine YB-1 antibody. 
Gluthatione-coated plates were incubated with GST-tagged recombinant YB-1 protein to allow binding of the 
GST to the plate and presentation of the YB-1 protein as the ELISA target without steric hindrance by the 
plastic surface. To assess the sensitivity of the reverse ELISA, murine antibody was diluted in 100µl of 
serum from healthy adult volunteers, and 1 µl of this dilution was further diluted in 29µl of blocking solution, 
yielding the final dilutions shown in the graph above. Antibody amounts were then detected via a secondary 
biotinylated anti-mouse antibody, as well as a streptavidin-coupled horseradish peroxidase for enzymatic 
quantification.  
 
4.1.4.3 Testing on clinical samples 
To detect YB-1 autoantibodies in NB patients, 3 µl of patient serum diluted with 24 µl of blocking 
solution to a total volume of 27 µl was incubated per well. Blocking solution was used as a 
negative control. Control sera of healthy children were used as an additional negative control to 
detect only NB-specific autoantibodies. The pooled NB patient and control sera used in the protein 
array experiments were tested initially to confirm the results of the protein array. Detection of 
51 
 
bound YB-1 antibody was achieved via the same secondary anti-human antibody used in the 
protein array experiments and streptavidin-biotin-conjugated horseradish peroxidase as described 
in section 3.13. BioFX® TMB Microwell Substrate (SurModics Inc.) was used for quantification. 
It was converted by the horseradish peroxidase in the immune complexes within 10-60 min. The 
reaction was stopped and fixed by addition of 100 µl BioFX® Stop Solution (SurModics Inc.) and 
the absorbance at 450 nm was measured.  
 
Serum samples from NB patients obtained at diagnosis were kindly provided by the serum bank at 
the University Hospital Göttingen, where samples were stored in a retrospective collection 
spanning more than 30 years of NB patient treatment in Germany. Considering the long time-span 
of collection and changing regard for standard collection procedures for patient samples, 
retrospectively collected samples were not collected or shipped using standard procedures to 
protect quality and comparability of protein samples. In the course of this project, new samples 
were collected at the University Hospital Essen, according to a standard operating procedure, 
developed to minimize protein degradation and allow better comparison between serum samples. 
Due to the rarity of this disease, however, these prospectively collected samples are few. Because 
of the possible differences in serum handling and quality, it was important to normalize individual 
serum samples in order to compare relative YB-1 antibody levels. YB-1 antibody levels were 
normalized to two different values representative for the total protein content of the serum. 
Initially, a prominent band was quantified in Coomassie brilliant blue R-stained gels on a gel 
documentation system, and later the amount of serum albumin was quantified using a commercially 
available ELISA (Human Albumin ELISA Kit; Assaypro). Standard spectophotometic protein 
quantification was not feasible due to the small volumes of patient sera available. Initially, 3 µl of 
each serum sample were separated on continuous gradient (4 % to 12 %) SDS-PAGE. 
Electrophoresis is described in section 3.11. One specific band at approx. 100 kDa was chosen 
because it was well defined and strong enough for colorometric measurement in all samples, but 
not such an abundant protein that differences in intensity were not detectable. Intensity of this 
protein band was measured in all lanes and used for normalization of antibody concentrations (Fig. 
11). All serum samples used in this study were later analyzed using a commercially available 
ELISA for human serum albumin. Due to higher reproducibility and easier comparison of samples, 
the albumin ELISA was superior to the Coomassie brilliant blue R gel-based quantification method 
for normalizing YB-1 antibody levels in serum samples. 
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Fig. 11: Example of one gel used to determine total protein concentration of patient sera. Total protein 
content was stained with Coomassie brilliant blue R, and 3 µl serum was loaded per lane onto a 4-12 % 
continuous gradient SDS-PAGE precast gel. Band intensity of the reference protein band (arrow) was 
colorometric measured on the BioDoc system, and used to normalize antibody levels. 
 
In the initial experiments analyzing the serum pools used in the protein array experiments, YB-1 
antibodies were detected in all the serum pools from NB patients (Fig. 12). Highest levels were 
detected in serum from patients with stages 4 NB, the most prognostically unfavorable stage. All 
serum pools from NB patients, regardless of tumor stage, contained significantly higher levels of 
YB-1 antibody than the serum pool from age- and gender-matched healthy children. This validates 
the results from the protein array, where YB-1 autoantibodies were also detected in serum from all 
NB stages compared to healthy controls. While quantification of the array results was not possible, 
the reverse ELISA detected an approximately 9-fold elevation of YB-1 antibody in stage 4, 4-fold 
elevation in stage 4S and 5-fold elevation in stage 1 compared to control serum.  
 
 
Fig. 12: Reverse ELISA detection of YB-1 antibody in pooled serum from NB patients with different tumor 
stages and healthy controls. Gluthatione-coated plates were incubated with GST-tagged recombinant YB-1 
protein to allow binding of the GST to the plate and present the YB-1 protein as the ELISA target. NB patient 
sera pooled according to stage and serum from healthy controls were incubated in wells overnight to allow 
binding of YB-1 antibodies in the serum. Antibody amounts were then detected via a secondary anti-human 
antibody coupled to horseradish peroxidase for enzymatic quantification. The experiment was performed in 
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duplicates, p-values were calculated using the student´s unpaired t-test and light emission is shown as bar 
graphs of the mean value with wiskers representing the standard deviation.  
 
Since the reverse ELISA was capable of detecting as low as a 1:45000 dilution of murine YB-1 
antibody, was therefore shown to be sensitive enough (Fig. 10) and required only 3 µl of serum, 
serum samples from individual patients could be analyzed. Fig. 13 shows YB-1 antibody levels of 
all tested single patient sera, normalized to human serum albumin concentration. Serum samples 
from two healthy adult volunteers were also included as negative controls and to assess possible 
age-specific differences for YB-1 antibody variability. YB-1 antibody levels in the adult sera were 
comparable to those in the healthy children.  
 
Fig. 13: YB-1 antibody concentrations in individual serum samples were analyzed using the YB-1 reverse 
ELISA. Stage 4s, stage 1, stage 2, stage 4 and stage 4 were retrospectively collected serum samples from NB 
patients.  PNB sera included all serum samples collected prospectively from NB patients treated at the 
University Hospital Essen according to an SOP. Controls include serum samples from all healthy children 
and adult controls include serum samples from two healthy adults. Concentration of serum albumin was 
measured using a commercially available ELISA for human albumin and HSA concentration was used to 
normalize samples for comparison. YB-1 antibody levels in the individual sera are shown as bars 
representing the mean value. 
 
Detected YB-1 antibody levels varied both between and within the NB stage groups. Statistical 
analysis was not conducted for differences between NB stages because of the limited sample 
number available for some groups and the lack of an obvious trend for elevated YB-1 antibodies in 
patients from a single stage. However, highest YB-1 antibody levels were detected in two serum 
samples from stage 4 NB patients as well as in one sample of a stage 4s patient and two of the three 
lowest levels were detected in serum samples from healthy controls. For further statistical analysis 
of the single patient sera, samples from NB patients were further divided into two subgroups based 
on the collection method of the sera as a quality control. Retrospectively collected samples from 
NB patients and serum samples prospectively collected from NB patients for this study using a 
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standard protocol were compared to controls in a box plot analysis (Fig. 14a). The group of NB 
patients showed significantly higher levels of YB-1 antibody in comparison to the controls, 
although the large range of the whiskers represents strong variation between individual patient 
samples within each group. Levels of YB-1 antibody in prospectively collected NB patient sera 
were not significantly different from antibody levels in the control sera although very few 
prospectively collected samples were available. Fig. 14b shows an alternative analysis of the data. 
Normalized YB-1 antibody levels of individual NB sera were now grouped by stage of disease and 
compared to controls. In addition to the control sera from healthy children, two adult controls were 
included in this analysis to assess the possible effect of patient age on YB-1 antibody levels. An 
unpaired t-test showed that significantly higher YB-1 antibody levels were detected in stage 4S and 
stage 1 patients in comparison to the controls. No significant difference was seen for the remaining 
stages or the adult controls. Overall, YB-1 antibody levels were significantly higher in serum from 
NB patients when data of all retrospectively collected NB sera was combined. The breakdown into 
individual stages showed that this increase is mostly due to high antibody levels in stage 4S and 1 
sera while stage 4 sera showed the most statistical spread.  
 
a)             b) 
            
 
 
Unpaired t-tests for Fig. 14a 
NB patients vs. controls: p = 0.0363 significant 
PNB sera vs. controls:  p = 0.2298 not significant 
PNB sera vs. NB patients: p = 0.2885 not significant 
 
Unpaired t-tests for Fig. 14b 
stage 4S NB vs. controls: p = 0.0233  significant 
stage 1 NB vs.   controls: p = 0.0066 significant 
stage 2 NB vs.   controls: p = 0.1018 not significant 
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stage 3 NB vs.   controls: p = 0.6424 not significant 
stage 4 NB vs.   controls: p = 0.1058 not significant 
 
Fig. 14: YB-1 antibody concentrations in serum from groups of NB patients, healthy control children and 
healthy adults. Relative YB-1 antibody concentrations of individual sera were grouped and shown as a box 
plots in Fig. 14a and 14b. The results of unpaired t-tests are listed to compare all groups shown in the box-
plots. NB patients included all retrospectively collected samples from NB patients with any stage. Controls 
include serum samples from all healthy children. PNB sera included all serum samples collected 
prospectively from NB patients treated at the University Hospital Essen according to an SOP.  
 
 
4.1.5 YB-1 is present in medium conditioned by NB cell lines 
Since autoantibodies were detected in serum from NB patients, it is possible that YB-1 was 
secreted by tumor cells or released by injured or dying tumor cells in amounts above what might 
normally be present in circulating serum, triggering an autoimmune response to this protein. It has 
been reported for monocytes and macrophages that YB-1 is actively secreted via a non-classical 
pathway where it acts as an extracellular mitogen for these cells (Frye et al. 2009). Medium 
conditioned by the NB cell line panel described above was analyzed for the presence of YB-1 
protein using western blotting. Cell growth was monitored thoughout the experiment to exclude 
unspecific protein release as a result of cell death resulting from overcrowded cultures. Various 
amounts of YB-1 protein were detected in conditioned medium from all NB cell lines analyzed 
(Fig.15). Highest levels were detected in conditioned medium from NB69 and SY5Y cell lines.  
 
        
Fig. 15: Extracellular amounts of YB-1 protein, detected in conditioned medium of NB cells.  Cells were 
cultivated in serum-free, supplemented RPMI for 72 h. Conditioned medium was then removed and 
centrifuged to remove nonadherent cells and cell debris. Conditioned medium was sterile filtered and 
protease inhibitors were added before concentrating it approx. 100-fold via centrifugation in Amicon© 
concentration units with a 5 kDa cut-off filter. Equal volumes were loaded onto SDS-PAGE, and western blot 
analysis was performed using an antibody against YB-1, followed by stripping the blot and detection of 
transferrin, a protein supplemented in equal amounts to the serum-free medium, and therefore, present in 
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roughly equal amounts in medium conditioned by every cell line. Transferrin was used as a loading control to 
assess differences in concentration between the samples. GAPDH was used as an additional control for 
unspecific release of protein. 
 
The amount of extracellular YB-1 did not correlate with the presence of MYCN-amplification. Cell 
death and subsequent release of intracellular proteins was excluded via staining with methylene 
blue which can be taken up by dead or injured cells but leaves intact cells colorless (Bonora 1982). 
To stain the cells with methylene blue, the supernatant was removed first and used for analysis of 
extracellular protein as described in section 3.9. Trypsin was added to cover the cell layer and 
incubated with the cells for 3-5 min. Trypsinized cells were mixed with 10 ml of complete medium 
and 200 µl methylene blue was added. After 1 min incubation, blue cells were counted under the 
microscope and a ratio of dead cells and overall cell number was calculated. Additionally, western 
blot analysis for the cytosolic protein GAPDH was performed for all conditioned media as an 
indicator for unspecific protein release from injured or dying cells. Low levels of GAPDH were 
only detected in conditioned medium from the SK-N-BE cell line. This cell line showed lowest 
amounts of extracellular YB-1, which renders unspecific release of YB-1 unlikely. Extracellular 
YB-1 levels were not correlated with indicators of increased nonspecific protein release. These data 
in addition to published reports that active secretion of YB-1 can occur indicate that extracellular 
protein most probably was a result of active and selective secretion of YB-1. 
 
 
4.2 ASSOCIATION OF YB-1 WITH KNOWN NEUROBLASTOMA MARKER PROTEINS 
 
4.2.1 YB-1 is associated with TrkA expression in the SY5Y cell line 
The possible correlation between YB-1 and other proteins known to play a role in NB development 
and pathogenesis were next addressed in NB cell culture models. Neurotropin receptors play an 
important role in the progression of neuroblastoma. While TrkA expression in the tumor is 
generally linked to disease stages with a better patient prognosis, TrkB expression is associated 
with an unfavorable prognosis (Ho et al. 2002). NB cell models stably overexpressing either the 
TrkA or the TrkB receptors are established in the laboratory. To examine a possible relationship 
between YB-1 and neurotrophin receptor expression, whole cell lysates of 3 NB cell lines stably 
expressing Trk-A were prepared in RIPA buffer, and YB-1 expression was compared to the 
parental cell lines using western blot analysis. YB-1 expression was significantly lower in TrkA-
expressing SY5Y cells, but no significant differences in YB-1 expression between TrkA-expressing 
and parental cells were observed for the NB69 and IMR-5 cell lines (Fig.16). Additionally, 
expression of the YB-1 protein in a TrkB-overexpressing NB cell culture model of the NB cell line 
SY5Y was compared to expression the parental cell line. No differences in YB-1 protein 
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expression were observed here (data not shown). Taken together, while there may be some 
relationship in terms of an inverse correlation between YB-1 and TrkA expression in the SY5Y cell 
line, this correlation was not seen in the other two tested cell line models and more research is 
needed in order to asses this correlation. 
 
a)        b) 
      
Fig. 16: YB-1 protein expression in TrkA-overexpressing NB cell culture models. a) Whole-cell lysates were 
prepared in RIPA buffer and analyzed by western blotting. GAPDH was used as loading control.  b) Band 
intensity was measured for YB-1 expression in SY5Y-TrkA and parental cells and normalized to GAPDH 
expression from 3 independent experiments. Bars represent the mean relative YB-1 expression ± standard 
deviation, and an unpaired t-test was performed to test for a significant difference in expression. 
 
 
4.2.2 MYCN activates expression of YB-1 and promoter binding analysis confims that both 
MYCN and c-Myc bind can the YB-1 promoter and activate transcription 
 
MYCN amplification is one of the major prognostic factors for NB, and is associated with poor 
outcome. Members of the Myc protein family bind as heterodimers to the E-box motif, CACGTG, 
which is also found in the YB-1 promoter (Norris et al. 1997). Although no clear association 
between YB-1 expression and MYCN amplification was observed for NB cell lines, many amplified 
cell lines did strongly express YB-1. Two different inducible NB cell culture models for MYCN 
were used to assess whether MYCN could affect YB-1 expression. The SH-EP-MYCN-ER cell line 
is an inducible system that holds transcriptionally inactive MYCN tethered in the cytoplasm to an 
engineered form of the estrogen receptor in the inactive state (Schulte et al. 2008). Treatment of the 
cells with 4-hydroxy-tamoxifen (4-OHT) binds the estrogen receptor allowing translocation of the 
fusion protein to the nucleus and activation of MYCN, which can be monitored via mRNA 
expression of the MYCN target gene, ODC1. Successful induction, resulting in a strong activation 
of MYCN and increased ODC1 transcription was confirmed after 72 h treatment with 200 µmol 4-
OHT/l culture medium. YB-1 expression was determined by semi-quantitative RT-PCR at this time, 
and a strong increase of YB-1 expression was detected in the induced SH-EP-MYCN-ER cell line 
in comparison to the untreated control. (Fig.17).  
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Fig. 17: Semi-quantitative RT-PCR showing mRNA expression levels of YB-1 and ODC1. MYCN activation 
was induced by 72 h treatment with 200 µmol 4-OHT/l culture medium, uninduced control cells were 
cultured in complete medium alone. Total RNA was isolated at 72 h and used for reverse transcription. 
GAPDH expression was used as an internal loading control. 
 
 
The Tet-21/N cell line is a conditional expression system in which tetracycline treatment reduces 
MYCN expression at the transcript level by at least 15-fold (Lutz et al. 1996). Tet-21/N cells were 
cultured in the presence of 1µg/ml tetracycline for 72 h, MYCN activity was monitored by 
assessing levels of ODC1 mRNA via semi-quantitative RT-PCR. At 72 h, ODC1 expression was 
reduced by 70-80 %. Tetracycline treatment for 72 h also strongly decreased YB-1 expression 
(Fig.18a). Western blot analysis of YB-1 and MYCN expression in whole-cell extracts from Tet-
21/N cells treated for 72 h with tetracycline also showed reduced levels of both MYCN and YB-1 
proteins (Fig. 18b). Fig.18c shows relative band intensities of YB-1 expression derived from the 
western blot in Fig. 18 b as a bar graph. YB-1 and GAPDH band intensities were measured and 
YB-1 expression was normalized to GAPDH expression. The data obtained using these two 
inducible model systems supports that MYCN expression or activity activates YB-1 expression 
either directly or indirectly as a downstream target. 
 
a)               
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b)     c) 
  
 
Fig. 18: Tetracycline-mediated repression of MYCN expression in Tet-21/N cells also reduced YB-1 
expression on both mRNA and protein levels. a) Cells were cultured either with or without 1 µg/ml 
tetracycline, and total RNA was isolated after 72 h then reverse transcribed. OCD1 and YB-1 expression were 
determined by semi-quantitative RT-PCR. GAPDH was used as an internal loading control. The experiment 
was performed three times. b) Whole-cell lysates were prepared in RIPA buffer after 72 h tetracycline 
treatment as in a, and analyzed via western blotting. YB-1 and MYCN proteins were detected, and GAPDH 
protein levels were used as a loading control. c) YB-1 and GAPDH band intensities of the western blot, 
shown in Fig. 18b were measured using the UVI chemi system (Biometra). YB-1 expression was normalized 
to GAPDH expression, and is shown as a bar graph.  
 
Since MYCN induced YB-1 transcription and the YB-1 promotor contains an E-box binding motif 
for MYCN, we asked whether YB-1 could be a direct target of MYCN. Binding of the MYCN or c-
Myc proteins to gene promoters was analyzed using ChIP-chip technology in cooperation with F. 
Westermann (DKFZ, Heidelberg). Either the MYCN or c-Myc protein was immunoprecipitated 
from cell lysates of a panel of NB cell lines (Kelly, IMR-5, SH-EP and SH-SY5Y cell lines as well 
as the WAC2 cell line, which constitutively expresses the MYCN transgene) after cross-linking 
DNA-protein complexes with formamide. Binding to the YB-1 promoter was assessed in a chip 
format to confirm a direct interaction of Myc proteins with the YB-1 promotor. MYCN bound to 
the CpG region of the YB-1 promoter region as well as to the canonical e-box in all cell lines 
examined (Fig. 19). Double binding peaks for H3K4me3 are characteristic for genes activated by 
Myc proteins using this methodology. The valley between the peaks is indicative of the area of 
transcriptional start. This type of curve indicates that Myc proteins bind to regions of the promoter 
to activate transcription, rather than distinctly to the canonical e-box. Marks for active transcription 
(H3K4me3), transcript elongation (H3K36me3) and transcriptional repression (H3K27me3) were 
also analyzed, showing that not only did Myc proteins bind to the promoter, but that transcription 
of the YB-1 mRNA occurred. Marks for transcriptional activation of YB-1 were strongly bound by 
Myc proteins relative to other promoters analyzed using this ChIP-chip platform. These data show 
that both MYCN and c-Myc can bind the YB-1 promoter and activate transcription in NB cells.  
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Fig. 19: Both MYCN and c-MYC proteins bind to the YB-1 promoter in NB cell lines. Binding was analyzed 
using ChIP-chip technology, and included histone marks for active transcription (H3K4me3), transcript 
elongation (H3K36me3) and transcriptional repression (H3K27me3). Binding strength is shown in a color 
scale ranging from green tones (no binding) to red tones (strong binding). Binding for lysates from the Kelly 
cell line are shown as an example, and binding from other cell lines are shown in Appendix I. 
 
 
4.3 INFLUENCE OF YB1 ON PROLIFERATION 
 
4.3.1 Downregulation of YB-1 reduces cell viability 
To further investigate the role of YB-1 for NB cells, YB-1 expression was downregulated by 
siRNA-mediated knockdown in NB cell lines. A role for YB-1 in proliferation has been described 
(Lu et al. 2005; Uchiumi et al. 2006) so proliferation and viability were assessed for NB cells after 
YB-1 downregulation. Since knockdown of YB-1 was shown to sensitize cells to cisplatin (Ohga et 
al. 1996), the cisplatin-resistant subline, SK-N-BEcp was included in the experiments as well. The 
SK-N-BE cell line and a cisplatin-resistant subline, SK-N-BEcp, were transfected with siRNA 
targeting YB-1 or mock control. Scrambled nonspecific control siRNAs were used as an additional 
control in initial experiments to exclude the possibility of nonspecific effects of siRNA 
transfection. mRNA expression of mock controls was comparable to expression in cells transfected 
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with scrambled control siRNA. YB-1 expression was quantified 72 h after transfection using real-
time RT-PCR and normalized against GAPDH expression. YB-1 expression was reduced by 48 % 
in SK-N-BE cells and by 61 % in SK-N-BEcp cells in relation to the mock-transfected controls by 
siRNA transfection (Fig. 20a). To assess the timepoint of maximum protein reduction, YB-1 
protein expression was analyzed via western blotting. The SK-N-BE and the SK-N-BEcp cell line 
were transfected with siRNA targeting YB-1 or mock control and whole-cell protein lysates were 
produced in RIPA buffer 48 h, 72 h and 96 h after siRNA transfection. Maximum reduction of YB-
1 expression (by 70-80 %) was obtained 72 h after transfection for both cell lines (Fig. 20 b/c). 
Microscopic observation of the transfected and mock-transfected cultures throughout the 
experiments showed no obvious changes in cell morphology or adhesion as indication of increased 
cell death following YB-1 downregulation.  
 
a) 
    
 
b)      c) 
      
 
Fig. 20: Efficiency of siRNA-mediated knockdown of YB-1 expression on mRNA and protein level a) Cells 
were transfected with siRNA targeting YB-1 or mock-transfected. Total RNA was isolated and reverse 
transcribed for real-time PCR using the Applied Biosystems StepOnePlus™ system. YB-1 expression was 
normalized to the GAPDH housekeeping gene. Relative expression was set to 100 % in the mock-transfected 
controls and bars show relative YB-1 mRNA expression. b) To quantify downregulation once on protein 
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level, whole-cell lysates were made in RIPA buffer 72 h after transfection, and analyzed on western blot with 
antibodies targeting YB-1 and GAPDH (as a loading control) c) Band intensities of the western blot in Fig. 
20b were measured, normalized against GAPDH protein expression. Bars show relative YB-1 expression.  
 
Transient transfection with siRNA targeting YB-1 maximally reduced YB-1 expression at the 
protein level 72 h after transfection, but could not eliminate YB-1 protein expression entirely. 
However, with a 70-80 % reduction in protein, siRNA-mediated knockdown should be useful to 
assess the impact of YB-1 on cell viability after cytotoxic drug treatment. YB-1 knockdown has 
been reported to increase the sensitivity of human epidermoid cells to cytostatic drugs (Ohga et al. 
1996), and it was of interest if this was also the case in NB cells. YB-1 was downregulated in SK-
N-BE and SK-N-BEcp cells, and cell viability in the absence and presence of cisplatin was 
monitored. For this, cells were transfected with siRNA targeting YB-1 or mock transfected, then 
cisplatin was added to the medium of the treatment group 48 h after transfection. Viability was 
assessed using a MTT assay 24 h later. These timepoints were chosen so that maximal YB-1 
protein downregulation occurred during cisplatin treatment. Knockdown of YB-1 significantly 
decreased viability of both SK-N-BE and SK-N-BEcp cells compared to the mock-transfected 
controls (Fig. 21). However, sensitivity of either cell line to cisplatin remained unchanged in cells 
with normal or repressed YB-1 expression. These results support a general involvement of YB-1 in 
proliferation, but no specific role in protection against cytostatic drug treatment. 
 
 
Fig. 21: YB-1 downregulation reduces cell viability in both parental and cisplatin-resistent SK-N-BE cells. 
Cells were transfected with siRNA targeting YB1 or mock-transfected, then treated with or without 12.5 
µg/ml or 17.5 µg/ml (for SK-N-BE or cisplatin-resistant cells, respectively) for 4 h starting 48 h after 
transfection.  Cells were incubated for another 24 h in regular medium until viability was assessed via MTT 
assay. The mean OD values for mock-transfected and untreated controls were set to 100 %, and bars show 
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mean viability relative to the controls ± S.D. Significance was calculated using the unpaired t-test and p-
values are shown above the comparison.   
 
 
 
4.4 ASSOCIATION OF YB- 1 WITH REPAIR AND DEVELOPMENT OF RESISTANCE IN NB 
 
4.4.1 YB-1 is involved in the repair of double-strand breaks in NB 
Double-strand breaks (DSBs) are a result of irradiation, but may also occur spontaneously during 
cell cycle progression. They are usually repaired fast, mainly though the repair pathway of non-
homologous end joining (NHEJ). It has been described in human embryonic kidney cells that YB1 
binds to various repair proteins of the NHEJ pathway, such as Ku80 (Gaudreault et al. 2004). To 
explore the role of YB-1 for repair mechanisms of DSBs in NB, cells were treated with siRNA 
targeting YB-1 and DSBs were counted per nucleus. Immunoflourescent labeling of γ-H2AX, a 
phosphorylated protein, which binds DNA at the site of DSB (Kuo et al. 2008) was used for 
detection of DSBs. γ-H2AX foci in the nucleus indicate the site of a DSB, and can be manually 
counted under the microscope. (Fig. 22a). In order to allow statistical analysis, 100 nuclei were 
counted for each sample. Cells were grown under standard conditions to observe the effect of YB-1 
depletion on DSBs throughout the normal cell cycle. Knockdown of YB-1 led to a significant 
increase of the average number of DSBs per nucleus in SK-N-BE cells. This accumulation of DNA 
lesions shows that YB-1 downregulation hampers the cells capability to repair DSBs efficiently, 
and points towards a role of YB-1 in repair mechanisms of NB. Interestingly, knockdown of YB-1 
did not lead to a significant increase of DSBs in the cisplatin-resistant SK-N-BEcp cells. 
 
a)           b) 
     
Fig. 22:  YB-1 downregulation increases DSBs in SK-N-BE cells a) SK-N-BE and SK-N-BEcp cells were 
grown on coverslips, and transfected with YB-1 targeting siRNA or mock-transfected for a control. Cells 
were fixed using 4 % paraformaldehyde 72 h after transfection. An immunoflourescently labeled antibody 
against γ-H2AX was used to visualize DSBs in the nucleus, and γ-H2AX foci (white arrows) were counted. 
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A total of 100 nuclei were counted per sample from 3 independent experiments. Bar 25 µm b) Box-plots 
show the combined results from all experimental data and statistical analysis. Boxes represent the 25th to the 
75th percentile of each group with the median of each group as the middle line; whiskers are drawn up to the 
minimum and maximum value of each group. ***p = < 0.0001; n.s. p = 0.1551 Experiments was performed 
in cooperation with Steffi Kuhfittig-Kulle.  
 
4.4.2 The effect of YB-1 downregulation on DNA adduct formation 
YB-1 downregulation increased the number of γ-H2AX foci in NB cells and heightened 
susceptibility to cisplatin, observed by the decrease in cell viability. To address whether other 
repair pathways might be influenced by YB-1 depletion, effects of knockdown on nucleotide 
excision repair (NER) were studied. NER is the primary mechanism used for the repair of 
intrastrand cross-links, which is the major lesion caused by cisplatin-induced DNA damage (Basu 
et al. 2010). SK-N-BE and SK-N-BEcp cells were transfected with siRNA targeting YB-1, and 
were pulse-treated with cisplatin 48 h after transfection cells as in previous experiments for 
cisplatin treatment. After an additional 24 h, cells were fixed on coverslips and stained with an 
antibody against DNA-adducts for quantification. Downregulation of YB-1 did not lead to 
significantly altered adduct quantity in SK-N-BE or SK-N-BE cp cells.  
 
 
Fig. 23: Quantification of DNA adducts in NB cells after YB-1 downregulation in the presence of cisplatin 
treatment. Cells were transiently transfected with siRNA targeting YB-1 or mock-transfected as controls. All 
cultures were treated with cisplatin for 4 h (SK-N-BE cells with 12.5 µg/ml and SK-N-BEcp with 17.5 
µg/ml), 48 h after transfection.  Cisplatin-induced DNA adducts (Pt-(GpG)) were detected by 
immunostaining. Antibody-derived signals were normalized for the total DNA content of a given cell, and 
expressed as arbitrary fluorescence units (AFU). 
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4.4.3 YB-1 localization in response to cisplatin 
YB1 is linked to various mechanisms in the cytoplasm as well as in the nucleus. The process of 
shutteling within the cells compartments is strictly regulated and it has been shown for several 
tumor types, e.g. non small lung cancer (Shibahara et al. 2001), that the cellular localization of YB-
1 is an important marker of prognostic stage or tumor malignancy. Since it has also been shown 
that translocation of YB-1 occurs in response to cytostatic agents (Koike et al. 1997; Stein et al. 
2001), the intracellular localization of YB-1 in response cisplatin treatment was assed here for NB 
cells. SK-N-BE and SK-N-BEcp cells were grown on cover slips and then kept in medium 
containing cisplatin for 24 h. Microscopic controls showed that cells were attached and evenly 
spread after the incubation period. Cells were subsequently stained with an immunoflourescent 
antibody against YB-1 to monitor the intracellular location. Nuclei were stained with 4′,6-
diamidino-2-phenylindole (DAPI). A diffuse staining of the nucleus as well as a cytoplasmic signal 
was observed in SK-N-BE cells (Fig.24). Cisplatin treatment did not significantly alter the YB-1 
distribution. However, a discrete formation of foci was observed in some regions but these changes 
could not be clearly allocated to the nucleus. The cisplatin-resistant subline, grown in regular 
medium, did show a more intensive, predominantly cytoplasmic, staining, Nuclei appeared larger 
and showed a grained structure of the immunoflourescent labeling. Addition of cisplatin did not 
significantly alter the distribution pattern but a minor increase of stained spots could be observed. 
Taken together, YB-1 showed a predominantly cytoplasmic localization in both cell lines analyzed. 
The grained and more intense staining of cisplatin-resistant cells might be because of increased 
YB-1 expression or may be due to accumulation of the protein. Cisplatin in the concentrations used 
in this experiment did not result in significant translocation but seemed to increase the overall 
amount of YB-1 protein levels in both cell lines. 
 
 
Fig. 24: Intracellular distribution of YB-1 protein in the absence and presence of cisplatin. Cells were grown 
on cover slips and incubated with cisplatin for 24 h. SK-N-BE cells kept in medium containing 7.5 µg/ml 
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cisplatin, cisplatin-resistant SK-N-BE were incubated with 12.5 µg/ml. Cells were fixed using 4 % 
paraformaldehye and stained with a primary antibody targeting YB-1 as well as a secondary antibody, 
fluorescently labeled with Texas Red.. 4′,6-diamidino-2-phenylindole (DAPI) was used to stain the nuclei. 
Bars 25 µm.  
 
4.4.4 Cisplatin treatment increases YB-1 expression 
YB-1 downregulation has been reported to increase the sensitivity of human epidermoid cells to 
cytostatic drugs (Ohga et al. 1996), and the results of the immunoflourescent staining for YB-1 
described in section 3.15 pointed towards increased expression of the protein in response to a 
cytostatic agent. While immunoflourescence is a good method to assess intracellular distribution, it 
is limited for quantifying changes in protein expression. Western blot analysis was performed using 
whole-cell RIPA extracts of SK-N-BE and SK-N-BEcp cells treated with cisplatin, and relative 
YB-1 protein expression was assessed. Western blot analysis showed a significant increase of YB-1 
protein in cisplatin-treated cells in comparison to the untreated controls for both cell lines (Fig. 25). 
The upregulation of YB-1 in response to cisplatin in NB cells indicates a role for YB-1 in 
responding to cytostatic agents. YB-1 upregulation may help the cells to deal with DNA damage 
and improve repair capacities.  
 
 
 
Fig. 25: Cisplatin treatment increased YB-1 protein expression in both parental and cisplatin-resistent SK-N-
BE cells. Cells were treated with cisplatin (12.5 µg/ml for the SK-N-BE cells and 17.5 µg/ml for the 
cisplatin-resistant cells) for 2h. Whole-cell lysates were prepared in RIPA buffer. The YB-1 and GAPDH 
proteins were detected via western blot analysis. Band intensity of both proteins was quantified, and YB-1 
expression was normalized to GAPDH expression. Relative YB-1 expression was set to 100 % for untreated 
controls of both cell lines to allow comparison. Bars represent the mean of at least 3 independent experiments 
with whiskers representing the standard deviation. Significance was assessed using an unpaired t-test.  
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4.4.5 YB-1 binds to various repair proteins 
The results of the experiments presented above indicate that YB-1 participates in DNA repair 
mechanisms in NB cells. To further explore this involvement, co-immunoprecipitation (Co-IP) 
experiments were used to detect YB-1 interactions with repair proteins. Whole-cell lysates were 
prepared in RIPA buffer and were precleared with Preclearing Matrix F (ExactaCruz, Santa Cruz) 
to remove proteins that unspecifically bind the co-immuoprecipitation matrix. Formation of the 
antibody-IP matrix complex and incubation with the precleared cell lysate was performed as 
described in section 3.12. Rat IgG was used as a negative control. To develop the assay and to 
establish optimal binding conditions for each antibody, the washing of the matrix was performed 
three times with PBS and/or, for more stringent conditions, with RIPA buffer. Best results were 
obtained for all antibodies when washed twice with RIPA and then once with PBS, each washing 
step was performed for 15 min on a rotary shaker at 4 °C. Proteins bound to the matrix were eluted 
and separated on a NuPAGE® BisTRIS 4-12 % polyacrylamide gradient gel, and 20 µl aliquots of 
the supernatent at each step were also analyzed by western blotting to control for the removal of 
non-specifically bound proteins during the washing of the matrix. An example of the Co-IP with 
Ku80, including supernatants from all washing steps is shown in Fig. 26.  
 
 
Fig. 26: Co-IP shows binding of YB-1 to the repair protein Ku80 in whole-cell NB lysate of NB cells. 
Whole-cell extracts of SK-N-BE cells were prepared in RIPA buffer. A preclearing step was performed as 
described in the methods section. Co-IP with a YB-1 antibody and a negative control (rat IgG) was 
performed with the precleared lysates. Bound YB-1 protein with its binding partners was eluted after several 
washing steps and YB-1 protein was detected in whole-cell lysates, the eluates and each supernatant using 
western blotting.  
 
Ku80, is involved in the NHEJ repair pathway, and was reported to interact with YB-1 in human 
293 embryonic kidney cells (Gaudreault et al. 2004). Ku80 was chosen as a positive control, and 
another protein from this pathway was selected, namely Rad51. In order to assess a second repair 
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pathway, XPC and ERCC1, which are involved in NER, were chosen. NER is the primary 
mechanism for the repair of cisplatin-induced damage, and even though YB-1 downregulation did 
not significantly abolished the repair of DNA adducts in NB cells, it was still shown that YB-1 was 
upregulated in response to cisplatin. Since a role of YB-1 in resistance to cisplatin has been 
described in literature for human epidermoid cancer cells (Ohga et al. 1996), binding of YB-1 to 
NER repair proteins may still be conceivable. Co-immunoprecipitations utilized Ku80, XPC and 
Rad51 antibody linked to beads (Immunoprecipitation Kit Santa Cruz Biotechnology) and whole-
cell lysates of SK-N-BE cells in RIPA buffer. Binding of YB-1 to Ku80, was verified for the NB 
cells (Fig. 27a). More YB-1 protein was detected in the eluate from XPC-coated beads than the 
eluate from the rat IgG-coated beads used in the control co-immunoprecipitation (Fig. 27b), 
indicating that XPC was also bound to YB-1 in the whole-cell lysates. Binding of the Rad51 
protein and YB-1 in whole-cell extracts was also detected compared to nonspecific binding to the 
control beads (Fig. 27c). To examine, whether binding of YB-1 to Ku80 is further enhanced in the 
presence of cytostatic agents, the co-immunoprecipitation was repeated using whole-cell lysates 
from NB cells treated 4 h with 12.5 µg/ml cisplatin, however, enhanced binding was not observed 
here (data not shown). 
 
     a)                                              b)                                                c) 
 
Fig. 27: Co-IP shows binding of YB-1 to the repair proteins Ku80, XPC and Rad51 in whole-cell NB lysate 
of NB cells. Whole-cell extracts of SK-N-BE cells were prepared in RIPA buffer. A preclearing step was 
performed as described in the methods section. Co-IP with Ku80, XPC and Rad51 antibody and a negative 
control (rat IgG) was performed with the precleared lysates. Bound YB-1 protein with its binding partners 
was eluted after several washing steps. Proteins were detected in whole-cell lysates and the eluates using 
western blotting.  
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5 DISCUSSION 
 
NB is one of the most common cancers of childhood, and early detection as well as efficient 
treatment options are crucial for patient survival. This study describes the detection of potential 
novel markers of NB via utilization of serum-derived autoantibodies. It also shows that 
autoantibodies against the YB-1 protein are elevated in serum from NB patients, with highest 
abundance in sera from stage 4 patients. YB-1 is detectable in medium conditioned by NB cell 
lines, most probably due to active secretion. The extracellular presence of YB-1 in the area 
surrounding the tumor would expose the protein to the immune system, and might trigger the 
formation of autoantibodies. Knockdown of the YB-1 protein in NB cells increased DNA double-
strand breaks and reduced cell viability. Co-immunoprecipitation experiments also showed that 
YB-1 was associated with proteins involved in various repair pathways, Ku80, Rad51 and XPC, in 
NB cells. YB-1 was shown to be a direct target of MYCN. Amplification of the MYCN gene is the 
strongest predictor of bad prognosis for NB known to date, and the fact that YB-1 is a MYCN 
target indicates that YB-1 could be an important factor in the development and progression on NB. 
 
Patient serum autoantibodies can be used for detection of tumor markers  
Autoantibodies in NB patient serum were used in this study to identify possible novel marker 
proteins for NB via protein array analysis. Antibodies against several proteins were specifically 
detected in serum from certain stages of NB. The two the most relevant candidate proteins were 
GPI, detected in serum from stage 1 NB patients, and YB-1, detected in serum from patients with 
all NB stages relative to healthy age- and gender-matched children. Multiple individual clones for 
YB-1 were detected in each analysis, and since these clones are directed against different parts of 
the YB-1 protein, it is highly unlikely to be a false negative. Based on this result, YB-1 was the 
best target identified using this methodology for further research. It has been previously reported 
that cancer patients sometimes show an immune response to self-proteins expressed by their tumors 
(Anderson et al. 2005), and that the level of antibody formation against an antigen varies according 
to tumor type, as shown for patients with non-small cell lung cancer (Bergqvist et al. 2003). 
Autoantibodies have also been detected in NB patients. Rodolfo et al. reported that 10 % of patients 
with stage III and stage IV tumors had evidence of antibodies to the NY-ESO-1 antigen (Rodolfo et 
al. 2003). Since a protein must be exposed to the immune system, cell surface or secreted proteins 
may be more apt to become targets of autoantibodies, and it is likely that proteins against which 
antibodies were detected on the array, are present outside the tumor cells. However, it is unclear 
what causes the immune system to react to some proteins while most of the others are still 
recognized as “self”. It has been described that self-proteins triggering an immune response are 
mostly altered in some form, rendering them immunogenic (Anderson et al. 2005). A structural 
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mutation of all proteins detected on the array seems unlikely since it would strongly hamper cell 
survival, so alternative triggers of autoantibody formation must be taken into consideration. It has 
been described that autophagy, a pathway which degrades and recycles proteins, promotes peptide 
transfer from autophagic vacuoles to the cell surface and subsequent MHC class II presentation 
(Dengjel et al. 2005). This, together with other autophagy actions, such as cytokine regulation, is 
thought to play a role in the loss of self-tolerance to molecules and may also provide an explanation 
for the formation of autoantibodies against intracellular proteins (Lleo et al. 2007). Autophagy is 
not only required for the normal turnover of cellular components, but is also associated with tumor 
development, where it assists the tumor to survive nutrient-limiting conditions, especially in the 
poorly vascularized internal region of the tumor (Shintani et al. 2004). The process of apoptosis has 
also been linked to formation of autoantibodies. Allina et al., have shown in biliary epithelial cells 
that intracellular molecules cleaved by caspases can generate cell-surface expressed autoantigens 
that may jeopardize self tolerance (Allina et al. 2006). Taken together, several possible pathways 
for the development of autoantibodies have been described and probably involve alteration or 
degration of the proteins as part of the process. Intracellular proteins can also become 
immunogenic via transport to the surface, either through secretion of the entire protein or though 
vesicular transport of peptides following autophagy.  
 
NB cells secrete GPI 
Antibodies against GPI were detected via protein array analysis in sera from patients with stage 1 
NBs. GPI, although mainly known as an enzyme in the glycolysis pathway, has been previously 
linked to cancer progression since, for example, it is upregulated in gastric cancer tissue and 
colorectal cancer and associated with poor prognosis for these specimen (Gong et al. 2005; 
Nakamori et al. 1994). Selective secretion of GPI by fibrosarcoma cells via a nonclassical active 
secretory mechanism has been reported (Niinaka et al. 1998). Antibodies against GPI have also 
been found in serum from patients with rheumatoid arthritis (Schaller et al. 2001), further 
supporting the possibility of autoantibody formation against principly intracellular proteins in 
disease states. Surprisingly, antibodies against GPI were detected in only stage 1 NB patients in 
this study, a stage associated with good patient prognosis, contrary to the association with poor 
outcome described in literature. However, detection of an autoantibody may indicate enhanced 
secretion of the protein or an unspecific release of at least a portion of the protein as a result of cell 
necrosis or autophagy. Both of which must not be associated with total protein expression in the 
tumor, and may also be a result of spontaneous tumor regression with subsequent protein release as 
well as immune response against the tumor. Both scenarios are likely for stage 1 NB. Extracellular 
GPI protein was detected in conditioned medium of all NB cell lines used in this study. During the 
course of collecting the conditioned medium, cultured cells appeared adherent and did not reach 
100 % confluency. Cultures were trypsinized after medium collection and both adherent cells as 
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well as cells from the conditioned medium were assessed by trypan blue. There was no correlation 
between the percentage of nonviable cells and the amount of GPI in the conditioned medium, so an 
unspecific release of cytoplasmic contents due to necrotic cell death was an unlikely reason for GPI 
in the medium. One report demonstrated active secretion of GPI by human umbilical vein 
endothelial cells, and showed that secreted GPI promoted tumor growth via angiogenesis 
(Yanagawa et al. 2004). Taken together, GPI can be secreted by some cell types and has been 
shown to trigger the formation of autoantibodies in humans. In this work, GPI was detected 
extracellularly in cultured NB cells, and autoantibodies were detected in the serum from patients 
with stage 1 NBs, hinting towards an active secretion of GPI by NB cells and a possible role in NB 
tumor immune response. Whether GPI secreted by NB cells stimulates angiogenesis could be 
assessed in a preclinical xenograft model where extracellular GPI is selectively blocked via an 
antibody and xenograft tumor growth as well as angiogenesis is monitored. According to the report 
by Anderson et al. (2005), a protein alteration may trigger the immune response. Therefore, whole 
genome sequencing analysis of larger tumor cohorts could additionally provide data on whether 
GPI is a target for mutation in specific subsets. 
 
NB patients show elevated YB-1 antibody concentrations  
Autoantibodies against the YB-1 protein were detected in serum from all NB stages in comparison 
to control serum. Detection of these autoantibodies was highly relevant due to the representation by 
many independent clones. Subsequent quantification via reverse ELISA confirmed elevated 
antibody levels in pooled NB sera in comparison to controls and also showed that highest levels 
were detectable in serum from patients with stage 4 NB. Further analysis of individual patient sera 
by reverse ELISA showed a high variability within the single patients. Median antibody 
concentrations of NB patients were significantly elevated in comparison to controls, further 
demonstrating the possible use of YB-1 as a marker for this disease. Interestingly, YB-1 antibody 
levels in the serum from individual NB patients varied largely, reflecting strong interindividual 
differences in antibody concentrations, also within the groups. Hypothetically, these differences 
could be caused by differences in tumor size or could also be a sign of enhanced autophagy, 
possibly due to tumor starvation and subsequent release of YB-1 peptides. Highest levels of YB-1 
antibody were detected in serum from two stage 4 patients; however, the median value was not 
elevated in comparison to the other NB stages. It might be possible that these two sera were 
responsible for the high antibody levels of stage 4 serum pools, detected in the initial experiment. 
These results show strong antibody expression of some stage 4 tumors which may provide evidence 
that YB-1 is more important for these highly aggressive stages. Analysis of a larger, prospectively 
collected patient cohort would allow a better statistical analysis and assumption about this. 
Additionally, it would then be possible to further break down the patient groups with different 
tumor stages, and correlate the antibody levels to other patient data, such as tumor size or age at 
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diagnosis.  Taken together, YB-1 antibody concentrations are elevated in sera of NB patients in 
comparison to controls. Although a significant difference for stage 4 tumors was only observed in 
pooled sera, some individual patients with stage 4 tumors did show very strong YB-1 antibody 
expression. 
 
The majority of the serum samples available were retrospectively collected. Six samples were 
prospectively collected using a standardized protocol designed to limit differences based on sample 
processing and storage. YB-1 antibody levels were less variable in prospectively collected sera. 
Although it did not reach statistical significance, the median YB-1 antibody level was slightly 
higher in prospectively collected serum samples from NB patients compared to controls. The small 
sample size is probably the reason why this difference did not reach significance. A recent 
publication described the detection and potential use of p53 autoantibodies as a biomarker for 
serous ovarian cancer, and the authors suggested that detection of autoantibodies might be affected 
by storage length (Anderson et al. 2010). Varying transport and storage times and conditions of the 
retrospectively collected serum samples might have affected the antibody concentrations, since 
measurable antibody concentrations in retrospectively collected sera could have been reduced by 
degradation. Although antibodies have a long half-life in serum and are relatively stable proteins 
(Anderson et al. 2008; Zhang et al. 2010), a standardized collection and storage protocol is crucial 
to reduce variability between samples and, thus, specificity of detection and comparability of 
results.  
 
What could the presence of YB-1 autoantibodies in patient serum tell us about the NB? One the 
one hand, elevated levels of YB-1 antibody might indicate a strong, possibly protective, immune 
response as proposed for high titers of her2/neu antibodies in breast cancer patients (Jager et al. 
1999). On the other hand, they could also be a useful surrogate biomarker for differences in tumor 
biology. It was shown that the presence of p53 autoantibodies is correlated with tumor burden and 
p53 mutation in breast cancer patients (Anderson et al. 2008). The presence of YB-1 antibodies 
might reflect characteristics of tumor progression in NB patients as well. Since very strong levels 
of YB-1 antibodies were found predominantly in stage 4 patient sera, an association of these 
antibodies with progression and bad prognosis appears possible. As discussed before, autophagy is 
a possible mechanism, leading to immunogenic responses against intracellular proteins (Lleo et al. 
2007). Since autophagy is used to maximize nutrition resources and associated with tumor 
development (Shintani et al. 2004) this would further point towards autoantibodies being a marker 
for malignancy. Further research on a larger patient cohort would be needed to find common 
patterns of YB-1 antibody formation in NB, but this research points towards YB- antibodies being 
a marker for prognostically bad tumor features found in some NB patients. 
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NB cell lines secrete YB-1 protein 
All NB cell lines tested expressed the YB-1 protein. YB-1 protein was also detected in the medium 
of cultured cells, and the amount present extracellularly was not correlated with cell death in the 
cultures, rendering active secretion as the most likely mechanism responsible for the extracellular 
presence. Active secretion of the YB-1 protein via a non-classical, vesicle-mediated pathway has 
been described for mesangial and monocytic cells (Frye et al. 2009), where extracellular YB-1 
stimulated migration and proliferation. YB-1 protein has also been previously detected in serum of 
healthy adults (Krings 2008), and the presence of autoantibodies in the tested NB sera in this work 
indicate that the protein is present extracellularly in vivo as well. It is as yet unclear whether 
increased levels of antibody in NB patients reflect larger extracellular YB-1 protein amounts. A 
highly sensitive detection method, such as a protein ELISA would be useful for this analysis. Since 
extracellular YB-1 is associated with proliferation, an active secretion of YB-1 from NB cells in 
order to stimulate tumor development may be possible. In conclusion, YB-1 is present in NB cells, 
secreted from them and is likely to also be present in human serum. Since extracellular YB-1 
stimulates tumor progression of mesangial and monocytic cells (Frye et al. 2009), it may play a 
similar role for NB tumor cells, and this aspect should be further investigated. 
 
Assessment of a possible correlation between neurotropin receptors and YB-1 
The neurotropin receptors TrkA and TrkB play a major role in the development of NB and NB cell 
models stably overexpressing Trk receptors (Eggert et al. 2002) were also examined in this study in 
order to asses a possible correlation to YB-1. While TrkA promotes growth inhibition, neuronal 
differentiation and inhibits angiogenesis in a NB xenograft model, TrkB is associated with 
biologically unfavorable NB (Nakagawara et al. 1994; Eggert et al. 2000). An inverse correlation 
of YB-1 to TrkA was observed in cell lysates of SH-SY5Y cells, one of the NB cell lines used in 
the research presented here. Since YB-1 is expressed in angiogenic endothelial cells of various 
tumors, such as glioblastoma, gastric or colon cancers, as well as in cultured tumor cells and YB-1 
knockdown inhibited growth of human umbilical vein endothelial cells (Takahashi et al. 2010), it 
might be possible that low levels of YB-1 is part of the mechanism involved to cause growth 
inhibition in tumors strongly expressing TrkA. It is tempting to speculate that downregulation of 
YB-1, as a result of enhanced TrkA receptor expression, could at least in part mediate the decrease 
in angiogenic activity in TrkA-expressing tumors, and consequently, contribute to the more 
favorable prognosis. However, so far data to support this hypothesis has only been derived from 
one cell line while the two other tested cell lines did not show a significant inverse correlation. 
Further research, especially from experiments utilizing in vivo models, is necessary to explore a 
possible relationship. Xenografts of SY5Y-TrkA cells, as compared with the parental SY5Y or 
SY5Y-TrkB cells, injected into nude mice have shown that tumor growth was remarkable repressed 
in SY5Y-TrkA xenografts (Eggert et al. 2002). To explore a possible involvement of YB-1 in this 
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signal-response cascade, an additional vector overexpressing YB-1 could be inserted in the SY5Y-
TrkA cell line to restore high YB-1 levels and possibly promote subsequent tumor growth. Since 
TrkB receptor expression is associated with biologically unfavorable NB, and YB-1 also seems to 
be associated with unfavorable tumor features, a correlation of both proteins was explored as well. 
Interestingly no such correlation was seen on protein level in the tested cell lines. In conclusion, 
YB-1 expression was inversely correlated to TrkA receptor expression in one of the cell lines 
examined here but no significant correlation was seen in the other tested cell lines. Further analysis 
will be needed to investigate if repression of the YB-1 protein contributes to TrkA-mediated 
processes that result in better patient prognosis. 
 
Assessment of a possible correlation between MYCN proteins and YB-1 
Genomic amplification of MYCN, causing overexpression of the MYCN protein, is the genetic 
aberration most consistently associated with poor outcome and tumor progression in NB (Brodeur 
et al. 1984; Seeger et al. 1985). It is also known that transgenic overexpression of MYCN is 
sufficient to induce NB in mice (Weiss et al. 1997). Therefore, a possible association with YB-1, 
which has also been previously linked to cancer progression, e.g. in breast cancer or glioblastoma 
(Janz et al. 2002, Faury et al. 2007), is of major interest for further research. NB cell lines with 
single-copy and amplified MYCN were examined in this dissertation research. They all expressed 
YB-1, but YB-1 expression levels were not correlated to the MYCN status of the cell line. 
However, protein expression is dependent on multiple features and difficult to compare across 
various cell lines. It has been shown in cancers without amplified MYCN and low MYCN 
expression levels that expression of c-MYC is often elevated (Sadee et al. 1987; Breit et al. 1989). 
A repression of c-MYC by MYCN, was also observed for MYCN-amplified stage 4S tumors 
showing an inverse correlation between MYCN and c-MYC as part of an autoregulatory loop, 
controlled via repression of each other at defined promoter sites. (Sadee et al. 1987; Breit et al. 
1989; Westermann et al. 2008). MYCN and c-MYC have common target genes (Westermann et al. 
2008), therefore, it is not possible to draw a conclusion for the relationship between YB-1 
expression based only on the MYCN amplification status. In order to examine the interaction 
between YB-1 and MYCN under defined conditions, inducible model systems were utilized in this 
work. It was shown that YB-1 is upregulated in response to MYCN induction and YB-1 
downregulation follows MYCN repression, demonstrating a regulation of YB-1 by MYCN. MYCN 
is known to bind the E-box motif, and the promoter region of YB-1 contains an E-box motif (Wu et 
al. 2007), so that regulation via direct interaction is possible. Further experiments were conducted 
to determine whether MYCN directly bound the YB-1 promoter to activate transcription. ChIP-on-
chip analyses not only showed binding of the MYCN, but also of the c-Myc protein to the promoter 
region of YB-1 as well as initiation and transcription of YB-1. These experiments show that c-
MYC can also bind to the YB-1 promoter when MYCN protein levels are low and activate 
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transcription. These findings may explain why no correlation between YB-1 was observed with 
MYCN amplification in cell lines, although the two proteins share a common pathway. The 
discovery that Myc proteins can directly regulate YB-1 may be relevant for processes involved 
with NB progression. YB-1 is involved in various processes required for cancer progression, and it 
is possible that at least some of these processes may be ultimately initiated or driven by an 
overexpression of either c-Myc or MYCN, resulting from either gene amplification or other 
mechanisms maintaining high MYC protein levels in NB cells. Consistent with our findings, it has 
been shown for ovarian cancer that YB-1 knockdown led to downregulation of known downstream 
targets of MYCN and c-myc, such as NDRG1, a protein involved in cellular differentiation (Basaki 
et al. 2006; Pflueger et al. 2009). Since the results presented in this dissertation show YB-1 
regulation though MYCN and Basaki et al. demonstrated a positive correlation between NDRG1 
expression and YB-1, it is possible that the effect of MYCN on NDRG1 is mediated via a pathway 
involving YB-1, which would highlight the importance of YB-1 in the regulation of Myc-
dependent proteins. It will be interesting to further investigate, if YB-1 knockdown also decreases 
expression of other known Myc-target genes, such as MRP (Norris et al. 1997) and thereby to asses 
if YB-1 is involved in other pathways of Myc-dependent gene regulation. In conclusion, it was 
shown here that both, MYCN and c-Myc, not only bind directly to the YB-1 promotor but also 
activate transcription. Additionally, a published report describes an effect on Myc-dependent 
proteins following YB-1 knockdown. Together this shows the importance of YB-1 as a 
downstream target of the Myc family of proteins and at least some involvement of YB-1 in Myc-
dependent gene regulation. 
Knockdown of YB-1 protein significantly decreased proliferation of SK-N-BE cells in normal 
medium as well in the presence of cisplatin. Equal results were obtained for the cisplatin-resistant 
SK-N-BEcp cells. Consistent with these findings, multiple publications have shown implications of 
YB1 in proliferation processes, namely that it activates genes associated with general pathways of 
proliferation, such as cyclin A, cyclin B1, matrix metalloproteinase-2 (MMP-2), and the MDR1 
gene (Jurchott et al. 2003; Uchiumi et al. 1993; Mertens et al. 1997). The decreased proliferation 
after YB-1 depletion is even more interesting in the cisplatin-resistant cell line, since YB-1 is 
involved in the development of resistance against cisplatin in human epidermoid cancer, mouse 
embryonic stem cells and melanoma cells (Schittek et al. 2007; Shibahara et al. 2004; Ohga et al. 
1996). All these publications describe increased sensitivity against cisplatin after YB-1 
downregulation, suggesting that it has protective capacity against cytotoxic effects of DNA 
damaging agents. Whether the lower proliferation seen in this study is due to increased 
chemosensitivity or because of proliferation defects, remains to be elucidated. Knockdown of the 
YB-1 protein was most successful 72 h after siRNA transfection, reflecting a long turnover time of 
the protein. Even though downregulation reduced protein expression by 80 %, this long incubation 
time complicated experiments because cultures reached confluency before the experiment could be 
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completed and the residual YB-1 protein may have been enough to maintain YB-1 functionality. 
Future experiments would benefit from a cell line, stably transfected with an inducible YB-1 
shRNA construct. However, knockdown of YB-1 has been published for multiple cell lines and it 
has been shown that even reductions of around 50 % are sufficient to strongly impair the 
chemoprotective properties of YB-1 protein (Ohga et al. 1996). In conclusion YB-1 is associated 
with multiple proteins involved in proliferation as well as in the development of resistance and it 
was shown here that YB-1 depletion reduces proliferation of cultured NB cells.  
 
Association of YB-1 with cellular repair activity 
Formation of double strand breaks (DSBs) is induced by irradiation, but also occurs spontaneously 
during cell cycle progression. DSBs are usually repaired fast, in higher eukaryotes, mostly via non-
homologous end joining (NHEJ) (Gaudreault et al. 2004; Fattah et al. 2010). Defects in this repair 
pathway will, therefore, lead to accumulation of DSBs. DSBs were quantified in NB cells after YB-
1 knockdown, and it was shown in this dissertation that YB-1 depletion significantly increased 
DSB accumulation. Similar effects were reported for breast cancer cell lines by Toulany et al, who 
showed that knockdown of YB-1 enhanced residual γ-H2AX foci after irradiation (Toulany et al. 
2011). Interestingly, the authors describe an Akt-mediated phosphorylation of YB-1 at Ser102 in 
response to irradiation and propose that phosphorylated YB-1 is responsible for the development of 
radioresistant cells. C-terminal phosphorylation has been previously described as a major 
regulatory mechanism of YB-1 (Sutherland et al. 2005), and it has been shown that 
phosphorylation also influences translocation and transcriptional activity of YB-1 (Wu et al. 2006; 
Basaki et al. 2006). Additionally, it has been described that, in cells with oncogenic K-RAS, YB-1 
is constitutively phosphorylated (Toulany et al. 2011). Although no K-RAS mutation has been 
described for the SK-N-BE cells used in this study, the cells do show a heterozygous point 
mutation of the N-ras gene (Moley et al. 1991). It has also been shown in another publication that 
the N-ras gene of SK-N-SH NB cells has transforming activity, while the normal N-ras gene does 
not (Taparowsky et al. 1983). However, as to this point, it is not clear, if YB-1 is constitutively 
phosphorylated in the cell lines used in this study and antibodies used here were not specific for 
phosphorylated YB-1 protein, but the finding that YB-1 knockdown led to significantly decreased 
proliferation strongly indicates functionally active YB-1 protein. In contrast to SK-N-BE cells, the 
cisplatin-resistant SK-N-BEcp did not show elevated levels of DSB after YB-1 downregulation. It 
was shown in breast cancer cells that cisplatin resistance is associated with overexpression of YB-1 
(Garand et al. 2011), so a possible explanation for the resistance towards irradiation might be that 
YB-1 protein levels are elevated in the cisplatin-resistant SK-N-BEcp, leaving enough residual 
activity after knockdown to prevent a major accumulation of DSBs. A complete knockdown would 
be necessary to further explore this theory. However, transient transfection will not be sufficient 
here; again a stably transfected inducible vector containing YB-1 siRNA would be useful. 
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Additionally, development of resistance towards cytotoxic agents is a multifactorial event and it 
might be that the resistant cells have developed additional ways of repair efficiency, such as 
involvement of the tumor suppressor protein p53 to prevent DSB accumulation (Basu et al. 2010). 
Development of resistance is one of the greatest challenges in NB therapy. YB-1 has been 
associated with resistance against various DNA-damaging agents, among them cisplatin and UV 
light, since it was shown that knockdown of the protein sensitizes cells against these agents (Ohga 
et al. 1996, Shibahara et al. 2004) and that development of this resistance leads to YB-1 
upregulation (Levenson et al. 2000). In this dissertation research, western blot analysis was 
performed from cell extracts of SK-N-AS and SK-N-AScp cells, and a significant increase of YB-1 
protein following cisplatin treatment was observed for both cell lines. Additionally, 
immunoflourescent staining of both cell lines pointed towards increased overall amounts of YB-1 
following cisplatin treatment. Taken together, YB-1 depletion leads to accumulation of DSBs, and 
cisplatin treatment increases YB-1 expression in NB cells. Both findings are consistent with 
published reports, and show the association of YB-1 expression with genotoxic stress in NB cells 
as well as the possible involvement of YB-1 in mechanisms of resistance and repair.  
 
The influence of YB-1 depletion on the formation of cisplatin-induced DNA adducts was analyzed 
in this dissertation research as well. Although adduct formation slightly increased in SK-N-BEcp 
cells after YB-1 knockdown, no significant change was observed in either of the tested cell lines. 
Unfortunately, the experiment could only be successfully performed once, limiting the 
interpretation of the results. It has been described in melanoma cells that downregulation of YB-1 
increased the sensitivity to cisplatin (Schittek et al. 2007), but according to the experiment 
performed here, no significant change in adduct formation was observed for NB. It might be that 
YB-1 is involved in other proliferation processes but not directly in the repair of cisplatin damage, 
since its knockdown does reduce proliferation but is not able to influence adduct repair. Consistent 
with this finding is the publication by Uchiumi et al., where YB-1 knock-out mice were shown to 
be embryonic lethal due to incomplete neural tube closure. The authors proclaimed an involvement 
of YB-1 in cell proliferation, since its knock-out led to a failure in morphological transformation of 
cultured cells (Uchiumi et al. 2006). However, additional analysis of cisplatin adduct repair in YB-
1 deficient cells would be necessary for a clear statement. Although literature describes that YB-1 
is involved in repair of cisplatin-damaged DNA, initial experiments performed in this dissertation 
research could not validate this, and more research is needed to show if YB-1 knockdown impairs 
adduct-repair or if YB-1 depletion results in proliferation defects. While DSBs are mostly repaired 
through nonhomologous end joining (Critchlow et al. 1998), the repair of intrastrand cross-links, 
the major lesion caused by cisplatin, is performed via the nucleotide excision repair (NER) system 
(Basu et al. 2010). An influence of YB-1 depletion on adduct repair was not seen in NB cells, 
however it has been described in literature that YB-1 does bind cisplatin-modified DNA and  
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interacts with PCNA, a protein involved in the NER (Nichols et al. 1992; Ise et al. 1999). To target 
the question of how YB-1 is involved in the various repair pathways of NB cells, a set of repair 
proteins pathways was analyzed for a possible interaction with YB-1. Binding of YB-1 to XPC in 
NB cells was shown here. XPC is widely known to be involved in the NER pathway, the main 
pathway for DNA adduct repair, where it is needed for the recognition of bulky DNA adducts, 
caused by chemotherapeutics, such as cisplatin (Neher et al. 2010). It was shown in this dissertation 
research that cisplatin exposure enhanced YB-1 expression and YB-1 binds XPC. However, YB-1 
knockdown did not impair the repair of cisplatin-caused DNA adducts. Therefore, an alternative 
explanation to involvement in the NER pathway, for the binding of YB-1 to XPC in NB must be 
considered. Recent studies show that XPC is not only involved in NER, but also plays a role in 
DSB repair or in base-excision repair (BER) tumor suppressor protein p53 to prevent DSB 
accumulation (D'Errico et al. 2006; Despras et al. 2007). An involvement of YB-1 via XPC in these 
repair mechanisms is, therefore, possible. Additionally, it was demonstrated that YB-1 binds the 
Ku80 and Rad51 repair proteins in NB cells. Binding of YB-1 to Ku80 was previously shown in 
human 293 embryonic kidney cells (Gaudreault et al. 2004), and this interaction was validated here 
for NB. The Ku70/Ku80 heterodimer, or Ku, is the central component of the nonhomologous end 
joining (NHEJ) pathway, responsible for the repair of DSBs (Postow et al. 2008). As shown above, 
YB-1 knockdown impairs the repair of spontaneously occurring DSBs in SK-N-BE cells and 
binding of YB-1 to Ku80 now additionally highlights the involvement of YB-1 in the NHEJ repair 
pathway. Rad51 is involved in the DSB repair via homologous recombination, where it binds to 
single- and double-stranded DNA and exhibits DNA-dependent ATPase activity (Benson et al. 
1994; Li et al. 2007). The binding of YB-1 to XPC, Ku80 and Rad51 demonstrates the connection 
of YB-1 to various repair pathways, and although this is just the first step in the recognition of YB-
1 involvement in repair mechanisms of NB, it indicates that YB-1 could be important for processes 
governing NB tumor progression or development of resistance. Assessment of the contribution of 
YB-1 in repair of NB cells has to be answered with further experiment such as in vitro NHEJ 
assays, where NHEJ efficiency can be assessed through conversion of monomeric linear substrate 
into multimers and circular products as shown in (Despras et al. 2007). 
 
It has been shown in several other entities, such as lung or breast cancer that not just the overall 
amount, but also the intracellular location of YB-1 is of consequence for progression and prognosis 
of cancer (Bargou et al. 1997; Shibahara et al. 2001). And, although, YB-1 does not seem to be 
directly involved in the repair of cisplatin-derived DNA adducts in NB, it is known that it binds to 
cisplatin-modified DNA (Ise et al. 1999). Therefore, the intracellular localization of YB-1 in the 
absence and presence of cisplatin was monitored via immunoflourescence. Diffuse staining of 
nucleus and cytoplasm was observed in SK-N-BE cells, no significant change occurred after 
treatment with cisplatin besides slightly more prominent fluorescent spots. Similar results were 
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obtained for the cp-resistant sub-cell line; in both cell lines YB-1 was mainly localized in the 
cytoplasm. However, consistent with reports that overexpression of YB-1 in breast cancers causes 
cisplatin resistance (Garand et al. 2011) it was observed here that overall immunoflourescent 
staining appeared more pronounced in the SK-N-BEcp cell line, even in cell culture medium 
without cytostatics, hinting towards elevated protein levels. Additionally, cisplatin exposure led to 
elevated levels of YB-1 protein in both cell lines as described above. These observations strengthen 
the role of YB-1 in the reaction of cells towards treatment with cisplatin. However, contrary to 
several publications where nuclear translocation of YB-1 following genotoxic stress has been 
described, no such translocation was observed here. However, they report, e.g. for adenocarcinomic 
human alveolar basal epithelial cells that the translocation occurs  in the presence of wild type p53 
(Zhang et al. 2003). The SK-N-BE cell lines used in this study is known to contain wild type p53. It 
has been described as well that, while the p53 wild type SK-N-BE cells line was derived from a 
patient before therapy, another cell line SKNBE(2c), was taken from the same patient after relapse 
past cytotoxic therapy. These SKNBE(2c) cells showed a mutated and non-functional version of 
p53  (Tweddle et al. 2001). This observation raises the question, whether the SK-N-BEcp cells used 
here, which were made resistant in our lab, do still possess functional p53. Sequencing analysis of 
the p53 gene would be required to exclude a mutant p53 which would hamper translocation of YB-
1. In addition, other factors, such as poor immunoflourescent staining, low YB-1 protein amounts 
or insufficient cisplatin treatment could be the reason, why no translocation could be observed here.  
 
 
Patient autoantibodies led to the identification of GPI and YB-1 as possible players in NB 
progression and the development of resistance. Deeper investigation of the systems in which YB-1 
is involved in NB cells identified that the protein is an important direct downstream target of Myc-
proteins and that YB-1 depletion significantly decreased cell proliferation and led to DSB 
accumulation while cisplatin treatment increased YB-1 expression in NB cells. Additionally an 
interaction of YB-1 with various repair proteins, namely XPC, Rad51 and Ku80 was shown. These 
observations show the importance of YB-1 for NB. Further research and in vivo studies will be 
necessary to asses the role of YB-1 as a possible future target for treatment of resistant tumors. 
Additionally the inhibition of YB-1 as a new downstream target of Myc-proteins may provide new 
insights into the carcinogenesis and possible therapy of MYCN-amplified tumors. 
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6 SUMMARY 
 
Neuroblastoma is one of the most common cancers of childhood, and early detection as well as 
efficient treatment options are crucial for patient survival. This study describes the detection of 
potential novel markers of neuroblastoma via utilization of serum-derived autoantibodies. It also 
shows that autoantibodies against the Y-box binding protein 1 (YB-1) are elevated in serum from 
neuroblastoma patients, with highest abundance in serum from stage 4 patients. YB-1 is detectable 
in medium conditioned by neuroblastoma cell lines, most probably due to active secretion. The 
extracellular presence of YB-1 in the area surrounding the tumor would expose the protein to the 
immune system, and might trigger the formation of autoantibodies. Knockdown of the YB-1 
protein in neuroblastoma cells increased DNA double-strand breaks and reduced cell viability. Co-
immunoprecipitation experiments also showed that YB-1 was associated with proteins involved in 
various repair pathways, Ku80, Rad51 and XPC, in neuroblastoma cells. YB-1 was shown to be a 
direct target of MYCN. Amplification of the MYCN gene is the strongest predictor of bad prognosis 
for neuroblastoma known to date, and the fact that YB-1 is a MYCN target indicates that YB-1 
could be an important factor in the development and progression of neuroblastoma. Additionally 
the inhibition of YB-1 as a new downstream target of Myc-proteins may provide new insights into 
the carcinogenesis and possible therapy of MYCN-amplified tumors. Neuroblastoma is a very 
heterogeneous disease and early detection as well as consequent patient monitoring and staging is 
crucial to prevent patient over- or undertreatment. Results of this study may help with tumor 
staging and YB-1 may be a possible future target for treatment of resistant tumors.  
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8 APPENDIX 
 
8.1 LIST OF ABBREVIATIONS 
 
% percentage 
°C degree celsius 
bp base pairs 
BSA bovine serum albumine 
cDNA complementary DNA 
CpG cytosine-phosphatidyl-guanosine dinukleotide 
ddH20 double distilled water 
dil. diluted 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleoside triphosphate 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
et al. and others 
FCS fetal calf serum 
Fig. figure 
FITC fluorescein isothiocyanate 
g gravity 
h hour 
Ig Immuneglobuline 
Kb kilo bases 
kDa kilo dalton 
MRI magnetic resonance imaging 
NB neuroblastoma 
ng nanogramm 
PAA polyacylamide 
PBS phosphate buffered saline  
PCR polymerase chain reaction 
RNA ribonucleic acid 
RNase ribonuclease 
RNP ribonucleoprotein particle 
RT room temperature 
SDS sodium dodecyl sulfate 
siRNA small interfering RNA 
Tab. table 
TAE tris-Acetat-EDTA-buffer 
Taq Polymerase Thermophilus aquaticus Polymerase 
Tris tris(hydroxymethyl)-aminomethane 
μg mikrogramm 
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8.2 LIST OF FIGURES 
 
Fig. 1:   Hypothetical model of the genetic origin of neuroblastoma 
Fig. 2:   INRG Consensus Pretreatment Classification schema  
Fig. 3:    Schematic representation of the structure of Y-box binding proteins 
Fig. 4:    Schematic diagram of the functional domains of YB-1 
Fig. 5:   The fetal brain protein array used for the detection of autoantibodies 
Fig. 6:   Graphical breakdown of the 20 most significant targets of autoantibodies detected  
Fig. 7:   GPI protein in conditioned media from cell lines  
Fig. 8:   Conditioned medium from NGP cells 
Fig. 9:   Whole-cell extracts of NB cell lines 
Fig. 10:  Reverse ELISA detection of serum with spiked-in murine YB-1 antibody 
Fig. 11:  Example of one gel used to determine total protein concentration of patient sera 
Fig. 12:  Reverse ELISA detection of YB-1 antibody in pooled serum from NB patients  
Fig. 13:  YB-1 antibody concentrations in individual serum samples  
Fig. 14:  YB-1 antibody concentrations in serum from groups of NB patients and controls 
Fig. 15:  Extracellular amounts of YB-1 protein 
Fig. 16:  YB-1 protein expression in TrkA-overexpressing NB cell culture models 
Fig. 17:  Semi-quantitative RT-PCR showing mRNA expression levels of YB-1 and ODC1 
Fig. 18:  Tetracycline-mediated repression of MYCN expression in Tet-21/N cells  
Fig. 19:  Both MYCN and c-MYC proteins bind to the YB-1 promoter in NB cell lines 
Fig. 20:  Efficiency of siRNA-mediated knockdown of YB-1 expression  
Fig. 21:  YB-1 downregulation reduces cell viability in SK-N-BE cells 
Fig. 22:   YB-1 downregulation increases DSBs in SK-N-BE cells 
Fig. 23:  Quantification of DNA adducts  
Fig. 24:  Intracellular distribution of YB-1 protein in the absence and presence of cisplatin 
Fig. 25:  Cisplatin treatment increased YB-1 protein expression in SK-N-BE cells 
Fig. 26:  Co-IP shows binding of YB-1 to the repair protein Ku80  
Fig. 27:  Co-IP shows binding of YB-1 to the repair proteins Ku80, XPC and Rad51  
Fig. 28:  MYCN and c-MYC proteins bind to the YB-1 promoter in the IMR5 NB cell line 
Fig. 29:  MYCN and c-MYC proteins bind to the YB-1 promoter in the SH-EP NB cell line 
Fig. 30:  MYCN and c-MYC proteins bind the YB-1 promoter in the SH-SY5Y NB cell line 
Fig. 31:  MYCN and c-MYC proteins bind to YB-1 promoter in the WAC2 NB cell line 
 
8.3 LIST OF TABLES 
Tab. 1:   General chemicals 
Tab. 2:   Chemicals for western blotting, ELISA and Co-IP 
Tab. 3:   Chemicals for cell culture 
Tab. 4:   Chemicals for PCR 
Tab. 5:   Primary Antibodies  
Tab. 6:   Secondary  Antibodies 
Tab. 7:   General plasticware 
Tab. 8:   Plasticware for cell culture 
Tab. 9:   Technical Equipment 
Tab. 10:  Cell lines used in this dissertation 
Tab. 11:  Antibodies and corresponding dilutions used in this dissertation project 
Table 12:  Autoantibody target proteins selected for further investigation 
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8.4 SUPPLEMENTARY DATA FOR BINDING ANALYSIS  
 
Fig. 28: Both MYCN and c-MYC proteins bind to the YB-1 promoter in the IMR5 NB cell line. Binding was 
analyzed using ChIP-chip technology, and included histone marks for active transcription (H3K4me3), 
transcript elongation (H3K36me3) and transcriptional repression (H3K27me3). Binding strength is shown in 
a color scale ranging from green tones (no binding) to red tones (strong binding).  
  
Fig. 29: Both MYCN and c-MYC proteins bind to the YB-1 promoter in the SH-EP NB cell line. Binding was 
analyzed as described above. 
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Fig. 30: Both MYCN and c-MYC proteins bind to the YB-1 promoter in the SH-SY5Y NB cell line. Binding 
was analyzed as described above. 
 
Fig. 31: Both MYCN and c-MYC proteins bind to the YB-1 promoter in the WAC2 NB cell line. Binding was 
analyzed as described above. 
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